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1. Introduction
Until recently, tuberculosis (TB) had become a neglected disease, particularly in children. It
was after the emergence of multi drug resistant TB, and the complications brought about by
the HIV/AIDS coinfection, that TB took centre stage again. The common perception has been
that children rarely develop severe forms of TB and that they do not contribute much to the
spread of the epidemic. Although this could be the case in non-endemic areas, where diligent
contact tracing is enforced, in children from endemic areas it is a different story as revealed by
an autopsy study conducted in Zambia which demonstrated that tuberculosis was a major
cause of death from respiratory disease (Chintu et al., 2002).
Children are particularly vulnerable to more rapid development of severe disease and death
after infection, and those with latent infection become the reservoir of disease reactivation in
adulthood, fueling the future epidemic (Nicol et al., 2011). Since focus has been on reducing
transmission, previous TB control strategies have not prioritized childhood TB (Zar and Pai,
2011). Due to the difficulty in establishing an accurate diagnosis of childhood tuberculosis, the
true extent of the tuberculosis-related morbidity and mortality suffered by children in endemic
areas is rarely appreciated (Chintu et al., 2002). For example, Regional Data from the WHO in
2007 showed that smear-positive TB in children aged under 14 years accounted for 0.6–3.6%
of reported cases but since about 95% of cases in children under 12 years of age are smear
negative, these data underestimate the true burden of TB. Furthermore, in countries with a
high prevalence of HIV infection, there has been a marked increase in the incidence and a
decrease in the peak age prevalence of infectious TB; thus, most cases now occur in young
adults, who are often parents of young children (WHO Report, 2009). This finding suggests
that children in developing countries will emerge as a group at high risk. In industrialized
countries, most childhood TB cases are detected through contact tracing and have good
outcomes. This is in contrast to the situation in low- and middle-income countries, where
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childhood TB is closely associated with poverty, overcrowding, and malnutrition, with
consequently higher death and lower treatment success rates (Nelson and Wells, 2010).
Studies have revealed that children contribute a significant proportion to the disease burden
and suffer severe tuberculosis-related morbidity and mortality, particularly in endemic areas.
TB is now among the 10 major causes of mortality among children, with a global estimate of
130,000 deaths per year (WHO Report, 2009). Mortality has a strong correlation with socioe‐
conomic status, underlying nutritional status and immunocompetence (Palme, 2002). TB has
also been reported to be the third most common cause of death in HIV-infected children with
a clinical diagnosis of acute severe pneumonia (Palme, 2002). With roughly a million cases
estimated globally each year (Walls and, Shingadia, 2004) and a much higher risk of severe
disease and death among young children than adults, paediatric TB remains a public health
emergency and this is particularly evident in developing countries with poor public health
infrastructure.
As in adults, the majority of cases occur in the 22 high burden countries, where a combination
of high transmission rates and a large proportion of the population under the age of 15 years
mean children account for up to 25-40% of cases, with incidence rates for paediatric TB ranging
from 60-600 per 100,000 per year (Nelson and Wells, 2004). Increasing rates of childhood TB
have also been reported in Eastern Europe in the wake of the explosive TB epidemic which
followed the break up of the Soviet Union (Walls and Shingadia, 2007). Even traditionally low-
burden countries have seen a rise in cases, mainly due to immigration from TB endemic areas.
In most countries of Western Europe and North America, where children account for 4-7%
cases, paediatric incidence rates vary from about 1 to 15 per 100,000 per year, although much
higher rates are observed in some cities, such as London (Newton et al., 2008).
Despite this huge disease burden, children's access to anti-tuberculosis treatment in most
endemic areas remains poor, as tuberculosis control programs focus predominantly on the
treatment of sputum smear–positive adults (Starke, 2002). Recent technological advancements
in diagnosis of TB in adults have not been validated in children and, similarly, trials of new
drugs and development of pediatric formulations of standard first- and second-line drugs are
lagging behind. As a result both research and surveillance data in the field of childhood TB
have been greatly limited. Further research into the epidemiology, immune mechanisms,
diagnosis, treatment and prevention of childhood TB is urgently needed to enhance our
understanding of TB in children which may provide wider insights and opportunities to
facilitate efforts to control TB in the population.
Another problem is that most programs for TB control are limited because they target and treat
only active cases (Graham, et al., 2004) when most TB cases in children present as latent
tuberculosis infection (LTBI) with active disease occurring mainly in developing countries
(Dogra, et al., 2007). Without treatment, the majority of infants aged under 1 year die due to
TB. Even with effective antimicrobial therapy, severe TB continues to occur in young children
(Ávalos and Montes de Oca, 2012). Priorities for future research should, therefore, enhance
collaborations between developing and developed nations.
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This chapter addresses some of the unique features of TB in children; presents existing and
novel diagnostic, therapeutic and preventative measures; and outlines important areas of
future research. The main challenges for future research are highlighted and in conclusion it
is emphasized that well-targeted interventions, improved resources, and improved political
commitment, may lead to a dramatic reduction in tuberculosis-related morbidity and mortality
among children.
2. Epidemiology of paediatric TB
2.1. Global disease burden of paediatric TB
Poor case ascertainment, lack of resources for active case finding in most settings, and limited
paediatric surveillance data from TB control programs all hamper efforts to define accurately
the global burden of childhood TB (Nelson and Wells, 2004). Until recently, under the WHO
Directly Observed Treatment Short Course (DOTS) strategy, only smear positive cases were
being reported for children, yet smears are seldom performed in many high burden settings
and most disease in children is smear negative.
Although limited surveillance data prevent reliable estimates of the contribution of TB to
childhood mortality, available data indicate that pneumonia is the commonest cause of
childhood death globally (Nelson et al., 2004) an implication that TB, being an important cause
of pneumonia in many settings (Scott et al., 2008), may contribute significantly to these global
childhood deaths. A necropsy study in Zambia found evidence of TB in 18% of HIV-positive
and 26% of HIV-negative children dying of pneumonia (Chintu et al., 2002) although more
robust regional data on the epidemiology of childhood TB are urgently needed to define the
true burden of disease, and to characterize current transmission rates and circulating strains.
2.2. Pathophysiology of TB in children
2.2.1. Natural history of TB in children
The natural history of TB in children and pediatric patients follows a series of steps in which
phase 1 occurs after an incubation period of 3–8 weeks after primary infection. This is followed
by appearance of well-defined signs that include fever, erythema nodosum, a positive
tuberculin skin test response, and formation of the primary complex visible on chest radiog‐
raphy. Phase 2 occurs 1–3 months after the phase 1 in which period, the bacillus can migrate
to other parts of the body via the blood and this represents the period of the highest risk for
the development of tuberculous meningitis and miliary tuberculosis in young children. This
is the phase where dissemination of the bacillus most frequently occurs. Phase 3 occurs 3–7
months after primary infection and is the period of pleural effusions in children greater than
5 years old and bronchial disease in children less than 5 years. Phase 4 presents after 1–3 years
after phase 1 and is during which the osteoarticular tuberculosis in children 5 years and below,
appears. Phase 5 occurs up to 3 years after phase 1 and it is presented after calcification has
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been completed. It is after this stage that manifestations of classical adult tuberculosis appear
(Marais et al., 2004).
Extrapulmonary tuberculosis or miliary TB is a complication of primary TB in young children.
It includes peripheral lymphadenopathy, TB meningitis, skeletal TB, and other organ involve‐
ment. Other unusual sites for TB include the middle ear, gastrointestinal (GI) tract, skin,
kidneys, and ocular structures (Marais et al., 2006). Lymph node involvement typically occurs
6-9 months following initial infection by the tubercle bacilli. More superficial lymph nodes
commonly are involved. Frequent sites of involvement include the anterior cervical, subman‐
dibular, and supraclavicular nodes. TB of the skeletal system may lead to involvement of the
inguinal, epitrochlear, or axillary lymph nodes. Typically, infected lymph nodes are firm and
non- tender with non erythematous overlying skin. The nodes are initially non-fluctuant.
Suppuration and spontaneous drainage of the lymph nodes may occur with caseation and the
development of necrosis (Marais et al., 2006).
Bone or joint TB or skeletal TB may present acutely or sub-acutely. Vertebral disease may go
unrecognized for months to years because of its indolent nature. Common sites involved
include the large weight-bearing bones or joints, including the vertebrae (50%), hip (15%), and
knee (15%). Destruction of the bones with deformity is a late sign of TB. Manifestations for
skeletal TB may include angulation of the spine (gibbus deformity) and/or Pott disease (severe
kyphosis with destruction of the vertebral bodies). Cervical spine involvement may result in
allantoaxial subluxation, which may lead to paraplegia or quadriplegia.
2.2.2. TB risk factors
Following infection children have a higher risk not only of progression to disease, but also of
extrapulmonary dissemination and death. Infants have a particularly high morbidity and
mortality from TB (WHO, 2007). While many factors including host genetics, microbial
virulence and underlying conditions that impair immune competence (as is the case with
malnutrition and HIV infection) determine the outcome of infection, it is likely that the high
rate of progressive TB seen in young children is largely a reflection of the immaturity of the
immune response. Risk factors for the acquisition of tuberculosis (TB) are usually exogenous
to the patient. Thus, the likelihood of being infected depends on the environment and the
features of the index case. However, the development of TB disease depends on inherent
immunologic status of the host. For example, tuberculosis has been reported in patients treated
for arthritis, inflammatory bowel disease, and other conditions with tumor necrosis factor
(TNF)-alpha blockers/antagonists.
2.2.3. Factors for acquiring paediatric TB disease
Neonatal CD4 cells appear intrinsically deficient in their capacity to express Th1 effector
function, partially attributed to hypermethylation of the proximal promoter of the IFN-γ gene,
(White et al., 2002) and this results in a highly restricted pattern of IFN-γ response to a variety
of stimuli (Kampmann et al., 2006). CD154 (CD40 ligand) expression is also significantly
reduced compared with adult cells. These findings of generally impaired cell-mediated
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immune responses in the neonate and young children raise the question of whether antigen-
specific immune responses to mycobacteria are equally affected. Delayed type hypersensitivity
(DTH) to purified protein derivative (PPD) may be absent in up to 40% of HIV negative
children presenting with extrapulmonary TB, (van der Weert et al., 2006) compounding the
difficulties of diagnosis in young children. However, studies measuring responses to neonatal
vaccination with M. bovis BCG demonstrate potent Th1 responses, possibly related to the
activating properties of BCG vaccine on the potent antigen-presenting cells (APC). Indeed
while the long term efficacy of BCG vaccination may be limited, it does offer protection against
disseminated disease in infants and young children. The risk of serious and potentially
devastating disease is nevertheless still high in the first two years of life, underscoring the need
for a better understanding of the determinants of host protection particularly in this vulnerable
age group.
In the natural history of childhood intrathoracic TB, primary infection before 2 years of age
frequently progresses to disease within the first 12 months (Marais, et al., 2004). Young age
and HIV infection are the most important risk factors for severe or disseminated disease; the
risk of disease progression decreases during childhood, least at 5–10 years of age, and increases
again during adolescence. Pulmonary parenchymal disease and intrathoracic adenopathy are
the most common clinical manifestations of pediatric TB, accounting for 60%–80% of all cases
(Jensen, 2002). Among extra-pulmonary manifestations, lymphadenopathy is the most
common (67%), followed by central nervous system involvement (13%) and pleural (6%),
disseminated (5%), and skeletal (4%) TB (Marais, 2006). Disseminated disease and TB menin‐
gitis are usually found in very young children (age, under 3 years) and/or HIV-infected
children (Starke, 2003). More research is required to identify better strategies for case detection
and contact tracing, especially in high-burden settings, and to study the role of genetic and
nutritional factors that protect children from TB infection and disease.
HIV-infected children are at risk of both atypical pulmonary presentation and extra-pul‐
monary  disease,  which  comprises  up  to  60%  of  TB  in  this  population  (Starke,  2003).
Symptom-based diagnostic approaches perform poorly, because other HIV-related condi‐
tions, such as lymphocytic interstitial pneumonitis, broncho-ectasis, and respiratory infec‐
tions  (including  viral  pneumonitis),  mimic  the  clinical  and  radiographic  features  of  TB
(Marais,  2007).  Lymphocytic interstitial  pneumonitis tends to occur in children aged less
than  two  years,  presents  with  recurrent  respiratory  symptoms,  and  is  associated  with
clubbing and generalized lymphadenopathy and a miliary TB-like picture on chest radio‐
graph.  Although these patients  improve temporarily with antibiotic  therapy,  antiretrovi‐
ral treatment is required for sustained benefit and to avoid development of chronic lung
disease.  In  the  short  term,  there  is  little  prospect  of  achieving  a  widely  available  gold
standard diagnosis of TB in children either by means of culture, microscopy, PCR, or se‐
rological testing. Consequently, clinicians must rely on clinical criteria, chest radiography,
and tuberculin testing,  and attempts must  be made to improve the predictive power of
available tools (Swaminathan and Rekha, 2010).
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2.2.4. Host genetic susceptibility to paediatric TB
The immunological responses to MTB are due to the interaction between the immature
immune system in children, the host, bacterial and environmental factors (Meya and McAdam,
2007). Genetic as well as acquired defects in host immune response pathways greatly increase
the risk of progressive disease (Kampmann et al., 2005). Results from genome wide linkage
studies suggest that TB disease susceptibility is highly likely to be polygenic, with contribu‐
tions from many minor loci (Hill, 2006) and a large number of TB susceptibility markers have
been identified from candidate gene studies as ‘disease-causing’ genes which include TIRAP,
HLA DQB1, VDR, IL-12β, IL12Rβ1, IFN-γ, SLC11A1 and MCP-1. However, to date the greatest
evidence to support an underlying genetic basis for TB has come from the discovery of single
gene defects predisposing to disseminated and often lethal mycobacterial disease. Most
observations were initially made in children with reduced ability to activate macrophage
antimycobacterial mechanisms through defects in the IFN-γ (Kampmann et al., 2005) /IL-12
pathway resulting in severe mycobacterial infection. However, subsequent studies have led
to description of mutations in five susceptibility genes (Ottenhoff et al., 2005) confirming that
up-regulation of the macrophage through the IL-12/23-IFN-γ pathway is a fundamental step
in the containment of infection with mycobacteria. However, despite a growing adult literature
on the role of candidate genes from this pathway, data from children is scarce. This is surprising
given the marked differences in TB pathophysiology in children, which may also reflect
differences in genetic factors. Further studies of TB genetics in well-defined paediatric
populations are therefore needed.
2.3. Impact of HIV epidemic paeditric TB
Studies demonstrating a higher risk of TB among HIV- children (Jeena et al., 2002) highlight
the essential role of cell mediated immunity (CMI) in preventing mycobacterial dissemination
(Tena et al., 2003). Poor CMI in HIV co-infection often results in disseminated disease,
especially in advanced stages of HIV-infection, resulting in poorer survival compared to HIV-
negative children (Palme et al., 2002). Risk of active TB in HIV co-infected children is related
to both CD4 count and more indirectly also to viral load (Elenga et al., 2005).Conversely,
restoration of cellular immunity with anti-retroviral therapy partially reverses TB susceptibil‐
ity (Kampmann et al., 2006).
The impact of the Human Immunodeficiency Virus (HIV) epidemic on the burden of childhood
TB has been less well characterized than for adults (Corbett et al., 2003). However, the observed
shift in disease burden to younger adults it has caused, suggests that children are at particularly
high risk of exposure as well as disease (Graham et al, 2001). Reported prevalence of HIV co-
infection among children with TB range from below 5%, in industrialized settings, to over 50%
in some high burden African settings (Nelson and Wells, 2004). However, it is often difficult
to draw reliable inferences about the effect of HIV on TB incidence or risk from these obser‐
vational data due to ascertainment bias or diagnostic bias; incomplete ascertainment of HIV
status and because denominator population data on the proportion of all children infected
with HIV are usually lacking. (For example, children with HIV are more likely to be investi‐
gated for TB and diagnosis is unreliable because it is affected by HIV status). Nevertheless an
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increased TB incidence and poorer outcome have been observed among HIV infected children
in a variety of settings (Palme et al., 2002) including an estimated 20-fold increased TB incidence
associated with HIV infection in a study from South Africa. Methodological constraints in some
studies may explain why this has not been a universal finding (Marais et al., 2007).
2.4. Nutrition and paediatric TB
Several observational studies from adults and children show an association between mal‐
nutrition  and  TB,  (Cegielski  and  McMurray,  2004)  although  proving  the  direction  of  a
causal link is challenging, as TB in itself causes wasting. Diagnosis is further complicated
by frequently false negative TST in malnutrition, reverting to positivity only once nutri‐
tion has improved. Nevertheless these observational data, coupled with experimental ani‐
mal data and impaired CMI observed in malnutrition, support its role as a risk factor for
childhood TB (Cegielski and McMurray, 2004). However the effect of differing types and
degrees of  malnutrition,  and the population at  risk due to  malnutrition in communities
where both are endemic, are yet to be defined.
Among micronutrients, vitamin D deficiency has been most extensively studied, and shown
to be associated with TB in UK immigrants. Its active metabolite 1-alpha, 25-dihydroxy-
vitamin D modulates the host response to TB infection in numerous ways, including the
induction of antimicrobial peptides such as Cathelicidin LL-37 (Martineau et al., 2007).
2.5. Host-pathogen interactions in paediatric TB
The relationship between MTB strain genotype and clinical manifestation of disease is poorly
documented in children. A study in the Western Cape Province of South Africa demonstrated
that the Beijing and Haarlem genotype families are significantly associated with drug resistant
TB in children (Marais et al., 2006). The high prevalence of Beijing and Latin American
Mediterranean (LAM) strains in children reflects considerable transmission of these genotype
families in this setting (Marais et al., 2006).
Genetic markers of virulence and transmissibility, (Lopez et al., 2003) and the ability to
modulate host cellular immunity have been described for the Beijing strain, HN878 (Reed, et
al., 2004). Similarly the East African-Indian lineage is characterized by an LSP (Large Sequence
Polymorphism) conferring an immune subverting phenotype that contributes to its persistence
and outbreak potential of this lineage (Newton et al., 2006). Strain differences in immunoge‐
nicity may result in reduced detection by TST (Anderson et al., 2006) as documented in a
London school contact tracing investigation - an extremely worrying phenomenon which may
lead to underestimates of the true global burden of TB and underscores the need for new
diagnostics. Most studies of strain-specific responses are derived from adult TB cases, and it
remains to be established whether results are equally applicable to children. Further research
to characterize strain differences in pathogenicity and induction of immune responses should
include children as well as adults.
Peadiatric Tuberculosis: Is the World Doing Enough?
http://dx.doi.org/10.5772/54953
377
2.6. Clinical spectrum of paediatric TB disease
The clinical spectrum of childhood TB also reflects differences in the balance between the
pathogen and the host immune response, with more severe disease resulting from either poor
or ‘over-exuberant’ attempts to contain the disease. Many cases of primary TB infection in
children are asymptomatic, self-healing and remain completely unnoticed or accidentally
discovered at a later stage (Marais et al., 2004). In previously healthy children, what determines
the differences in the host/pathogen interactions that lead to successful containment as
opposed to progressive disease remains largely unknown. However, age and immunodefi‐
ciency are important factors. Thus, while an exuberant immune response, in immunocompe‐
tent adolescents, tends to result in adult-type, cavitating disease, (Marais et al., 2005) in young
children and/or HIV co-infection, poor CMI is thought to allow unrestrained proliferation of
bacilli with progressive parenchymal lung damage (with or without cavity formation)
dissemination (Marais et al., 2005)
While dissemination can occur to almost any site, TB meningitis (TBM) is one of the commonest
consequences of extra-pulmonary TB and develops three to six months after primary infection
(Donald and Schoeman, 2004). It is also the most severe and potentially devastating form of
childhood TB with mortality or significant long term neurological sequelae occurring in almost
50% of cases (Thwaites and Tran, 2005). Anatomical differences in children, compared with
adults, also modify the presentation of TB. Complications arising from enlarging lymph nodes
and small airways are common in children less than five years of age (Marais, et al., 2004;
Marais et al., 2005). Post-primary TB can result in upper-lobe pulmonary consolidation and
cavitation with highly infectious patients, more likely to be seen in older children.
HIV infection often mimics TB associated signs and symptoms, such as weight loss, failure to
thrive and chronic pulmonary symptoms, corroborating the diagnostic difficulties (reviewed
in references (Marais et al., 2007). In turn, the treatment of HIV with ART can result in
unmasking signs and symptoms of underlying LTBI or active TB in the form of immune
reconstitution disease (IRD) (Walters et al., 2006) in young children is largely a reflection on
the immaturity of the immune response.
2.7. Differences in childhood immune responses to TB
The alveolar macrophage is the first line of defense in the innate immune response to TB
and  plays  a  critical  role  in  amplifying  the  response  to  infection.  Studies  in  the  animal
and human host have consistently demonstrated reduced microbial killing and diminish‐
ed monocyte recruitment to the site of infection in infants compared to adults. Thus im‐
pairment  of  innate  pulmonary  defenses  in  the  neonate  and  infant  may  allow
mycobacteria  to  overwhelm the effects  of  the innate immune system prior  to  the initia‐
tion of an antigen-specific immune response.
Antigen presentation by dendritic cells (DC), the major antigen-presenting cell (APC) in the
lung, and the efficiency with which naïve T cells respond to antigen, also appears less effective
in infants and may contribute to the delay in initiating an appropriate antigen-specific
response, resulting in development of active disease. Blood derived DCs are functionally
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immature at birth relative to adult DCs and continue to express a less differentiated phenotype
throughout early childhood (Upham et al., 2006). Some studies also suggest that neonatal APCs
lack the capacity to deliver important Th1 polarising signals to T-cells. Their capacity to
synthesise interleukin (IL)-12, a key APC-derived cytokine, matures slowly during childhood
(Upham et al., 2002) and neonatal, monocyte-derived DCs have a specific defect in IL-12p35
expression (Goriely et al., 2001). IL-12 is critical for the initial phases of Th1 polarisation and
also for maintaining the efficiency of the interferon (IFN)-γ transcription machinery in Th1
effector cells (Goriely et al., 2001).
2.8. Latent tuberculosis in children
2.8.1. Detection of the infection
Transmission within a community is measured by the Annual Risk of Infection (ARI) (Rieder,
2005). Infection rates rise with increased exposure in toddlers, around the ages of school entry
and with increased social mobility in late teens and early adulthood (Marais et al., 2004). ARI
is traditionally estimated using childhood tuberculin surveys, although this has limitations
due to the poor specificity of the tuberculin skin test (TST), particularly where Bacille Calmette
Guerin (BCG) vaccine is given at birth and non-tuberculous mycobacteria (NTM) are endemic.
T-cell based interferon gamma release assays (IGRAs) may offer a more specific alternative
(Dinnes et al., 2007), but have not yet found a use in this context due to their cost, ethical
concerns about venepuncture in healthy children (Rieder, 2005), and uncertainty about the
significance of a positive result for later development of active disease. Threfore, differences
in the pathophysiology and clinical presentation of TB in children make diagnosis more
challenging than in adults (Shingadia and Novelli, 2003) and the definitions of latent infection
and disease, are less clear cut (Marais et al., 2004).
2.8.2. Activation from infection to disease
Following infection, several factors appear to influence the balance of risk between latent TB
infection (LTBI) or progression to active disease, including age (Marais et al., 2004) and
nutritional (Cegielski and McMurray, 2004), vaccination and immune status (Chen, 2004).
Children are at much higher risk of progression to active disease than adults. This risk is
greatest for infants and children under 2 years of age (Marais et al., 2004). Active surveillance
data from the pre-chemotherapy era suggest that the majority of children develop radiological
abnormalities following infection, including 60-80% of children less than two years. However,
less than 10% of those are notified, suggesting the disease is controlled by the host immune
response in most cases (Marais et al., 2004). This has implications for case definitions based on
radiological findings. Overall the risk of disease is highest among infants and in late teens,
with the lowest risk between 5 and 10 years - the so-called “safe school years” (Marais et al.,
2004). Most disease occurred in the first year following infection (Marais et al., 2004). Thus
because disease in young children reflects recent infection, rather than secondary reactivation,
the paediatric disease burden potentially provides a useful measure of current transmission
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within a community, Marais et al., 2005) including multi-drug resistant (MDR) (Schaaf et al.,
2006) and extensively drug resistant (XDR) strains.
3. Challenges presented by paediatric TB in the field of diagnosis and
treatment
3.1. Concepts from the natural history of disease
The pre-chemotherapy literature documented the natural history of tuberculosis in children.
Unfortunately, clinicians and researchers have limited access to these important studies as they
were conducted before 1950 and are not included in modern electronic databanks. Since the
discovery of safe and effective antituberculosis treatment, conducting studies on the natural
history of disease became unethical and therefore these historic disease descriptions remain
invaluable today. The pre-chemotherapy literature provides a strong body of evidence;
multiple studies monitored large cohorts of children for prolonged periods of time and
carefully documented the development of disease after primary infection with Mycobacterium
tuberculosis. A critical review of the natural history of disease identified three central concepts
that are important to consider when addressing current and/or future challenges in the field
of childhood tuberculosis: (1) the need for accurate case definitions, (2) the importance of risk
stratification, and (3) the diverse spectrum of disease pathology, which necessitates accurate
disease classification (Marais et al., 2004).
3.2. Challenge of case definition
Accurate case definition revolves mainly around the ability to differentiate primary infection
from active disease. Primary infection is believed to occur when a previously uninfected child
inhales a single infectious aerosol droplet, which may contain fewer than five bacilli that
penetrate into a terminal airway. A localized pneumonic process, referred to as the primary
parenchymal (Ghon) focus, results at the site of organism deposition. For the first 4–6 weeks,
unrestrained multiplication occurs within the Ghon focus and bacilli drain via local lymphatics
to the regional lymph nodes and beyond. The upper lobes drain to ipsilateral–paratracheal
nodes, whereas the rest of the lung drains to perihilar and subcarinal nodes, with dominant
lymph flow from left to right (Marais et al., 2006). The Ghon complex is represented by both
the Ghon focus, with or without some overlying pleural reaction, and the affected regional
lymph nodes (Marais et al., 2006).
Occult dissemination frequently occurs during this early proliferative phase before cell-
mediated immunity is fully activated. Bacteriologic cultures collected at this time may be
positive; Wallgren demonstrated in the 1930s that M. tuberculosis is sometimes recovered from
recently infected children who are not diseased. Therefore, with active contact tracing and
aggressive screening that includes the collection of mycobacterial cultures in asymptomatic
children it is not unexpected to find some positive cultures in recently infected children who
are not diseased. This illustrates the overlap that exists between recent primary infection and
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case definitions of disease that rely exclusively on bacteriology. It is important to consider this
overlap when case definitions are formulated for research purposes, particularly within the
contact setting, although it is less relevant in everyday practice where there is no reason to
obtain cultures from completely asymptomatic children.
Uncomplicated hilar adenopathy remains the most common disease manifestation in children
and is usually regarded as the hallmark of primary tuberculosis. However, the prechemother‐
apy literature documented transient hilar adenopathy in the majority (50–60%) of children
after recent primary pulmonary infection, of whom only a few progressed to disease (Marais
et al., 2004). The natural history of disease illustrates that progression to disease is indicated
by the onset of persistent, nonremitting symptoms, referred to as the breakpoint of clinical
significance whereas the complete absence of symptoms usually indicates good organism
containment (Marais et al., 2004). By convention, asymptomatic hilar adenopathy is currently
treated as active disease, although early experience with isoniazid alone demonstrated that
one-drug therapy was sufficient in these cases. In terms of pathophysiology, microbiology,
and natural history, asymptomatic hilar adenopathy is more indicative of recent primary
infection than active disease (Marais et al., 2004).
This indicates that radiologic signs should be interpreted with caution in the absence of clinical
data. The entity of so-called asymptomatic tuberculosis, where the case definition rests
exclusively on radiographic criteria, is a case in point. High-resolution computed tomography
is the most sensitive tool available to detect hilar adenopathy (Andronikou et al., 2004), as
demonstrated by the fact that in children with recent M. tuberculosis infection and a normal
chest radiograph, prominent intrathoracic nodes are frequently demonstrated by high-
resolution computed tomography. Particular caution is required when interpreting the
relevance of these radiologic signs in the absence of clinical data. It is important to point out
that there is no role for high-resolution computed tomography in the evaluation of asympto‐
matic, immune-competent children exposed to M. tuberculosis.
In reality, differences in patient selection may result in the use of different functional case
definitions even though the definitions appear similar on paper. In non-endemic areas where
active contact tracing is diligently enforced, more children with transient radiologic signs
indicative of recent primary infection will be identified, and those with active disease will be
diagnosed at an earlier, less advanced stage. Active contact tracing is rarely enforced in
endemic areas and children usually present to health care facilities with suspicious symptoms
and more advanced disease (Marais et al., 2006). Unlike asymptomatic contacts in which visible
radiologic signs probably indicate recent primary infection only, radiologic signs in sympto‐
matic children indicate active disease. From a research perspective it is important to be aware
of these differences, as inconsistent case definitions may confound the scientific interpretation
of results. In everyday practice, distinguishing between the signs and symptoms of recent
primary infection and active disease is less relevant in high-risk children (less than 3 years of
age and/or immune compromised) in whom infection frequently progresses to disease,
sometimes with rapid disease progression.
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3.3. Problems of risk stratification
The natural history of disease demonstrates that age is the most important variable that
determines the risk to progress to disease after primary M. tuberculosis infection in immune-
competent children (Marais et al., 2004). Infants are at the highest risk (Marais et al., 2004) and
the risk drops but stays appreciable in the second year of life, to reach its lowest level in children
infected between 5 and 10 years of age (Marais et al., 2004). Children with human immuno‐
deficiency virus (HIV) infection and/or other forms of immune compromise, such as severe
malnutrition, seem to experience a similar high risk as the very young (less than 2 years of
age), immune-immature children (Marais et al., 2004). The vast majority (more than 95%) of
children who progress to disease do so within 12 months of primary infection and, therefore,
it seems prudent to categorize all children less than 3 years of age and/or immune-compro‐
mised children as high-risk. Because of the frequency and rapidity with which disease
progression may occur, exposure to and/or infection with M. tuberculosis warrants treatment
intervention in this high-risk group (Marais et al., 2004).
Immune-competent children of at least 3 years of age are at low risk of progression to disease
after primary infection. However, as the vast majority of children in endemic areas become
infected after 2 to 3 years of age, these low-risk children still contribute a significant percentage
to the total disease burden. In addition, although these children are at low risk to progress to
disease, latent infection with M. tuberculosis does pose the risk of future reactivation of the
disease. In non-endemic areas, where transmission rates are low and eradicating the pool of
latent infection is an achievable aim, the provision of preventive therapy to these low-risk
children is warranted. In endemic areas, where the majority of disease in immune-competent
adults results from ongoing transmission and not from reactivation (Saiman et al., 2001), the
provision of preventive therapy after exposure and/or infection becomes less relevant. The
major diagnostic challenge in this low-risk group is the differentiation between latent infection
and active disease (Marais et al., 2004). Fortunately, active disease is accompanied by persis‐
tent, non-remitting symptoms and disease progression is slow, which provides a window of
opportunity for symptom-based diagnosis (Marais et al., 2004).
3.4. Difficulties in classifying disease diversity
Childhood tuberculosis is often reported as a single disease entity, although it represents a
diverse spectrum of pathology (Marais et al., 2004), and one of the obstacles has been the lack
of standard descriptive terminology. Accurate disease classification is important, because of
its prognostic significance and to facilitate scientific communication and optimal case man‐
agement. Within the Ghon focus, containment is usually successful, but disease progression
may result from either poor or “excessive” containment. Poor containment and unrestrained
organism proliferation may cause progressive parenchymal damage, with ultimate break‐
down of the Ghon focus. Infants (Dinnes et al., 2007) and HIV-positive children (Pai et al.,
2004), who have poor cell-mediated immune responses, are most vulnerable to this type of
cavitation. In contrast, immune-competent adolescents seem to mount an “excessive” (dam‐
aging) immune response in an attempt to contain the organism. The exact immune mechanisms
underlying adult-type disease remain uncertain, but it is a striking observation that it emerges
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only as children enter into puberty (Marais et al., 2004). It is important to remember that
children with adult-type disease are frequently sputum smear–positive and that they do
contribute to disease transmission (Cegielski and McMurray, 2004), particularly in congregate
settings such as schools.
Complications that arise from affected lymph nodes are most common in children less than 5
years old, because of exuberant lymph node enlargement and small airway size (Marais et al.,
2004). Extraluminal compression results when the airway is encircled by enlarged lymph
nodes and associated inflammatory edema (Marais et al., 2004). Intraluminal obstruction
results from polyps or granulomatous tissue that develops secondary to inflammatory changes
in the bronchial wall, or when caseous material is deposited into an airway after lymph node
eruption (Marais et al., 2004). Radiologic signs vary from segmental or lobar hyperinflation
with partial obstruction and a check-valve effect (Marais et al., 2004), to segmental or lobar
collapse with total obstruction and resorption of distal air (Marais et al., 2004). The pathology
that results from the aspiration of caseous material is influenced by the dose and virulence of
the bacilli aspirated. The pathology may range from transient parenchymal consolidation,
resulting from a pure hypersensitivity response to dead bacilli and/or toxic products, to an
expansile pneumonic process with progressive caseating pneumonia in the affected segment
or lobe (Marais et al., 2004). Expansible caseating pneumonia frequently leads to parenchymal
destruction and cavity formation.
Thus, cavitary disease in children may result from three distinct pathologic processes: (1) poor
containment at the site of organism deposition (very young and/or immune-compromised
children); (2) aspiration of live bacilli when a diseased lymph node erupts into an airway, with
destructive caseating pneumonia in the distal segment or lobe (children less than 5 year of
age); and (3) adult-type disease (mainly children greater than 10 year of age). The fact that
immune-competent children 5 to 10 yr of age experience the lowest risk to progress to disease
after primary infection with M. tuberculosis is an interesting immunologic phenomenon that
is poorly understood. A better understanding of age-related differences in the immune
response to M. tuberculosis may provide important insight into immune correlates of disease
and protection.
Disseminated disease occurs predominantly in very young (immune-immature) and/or
immune-compromised children, such as the HIV-infected or severely malnourished (Pai et al.,
2004; Shingadia and Chen, 2004). These children have suboptimal cellular immune responses
and demonstrate poor containment of the organism, both within the regional lymph nodes
and at the multiple sites of occult dissemination. TB meningitis (TBM) is the most dangerous
complication of disseminated disease, occurring in 20 to 30% of cases (Chen, 2004).
3.5. Challenges in diagnosis
3.5.1. Overview of diagnostic challenges
Diagnostic difficulties pose the greatest challenge to childhood TB management (Marais and
Pai, 2007). There are diagnostic complications because: (i) TB can mimic many common child‐
hood diseases, including pneumonia, generalized bacterial and viral infections, malnutrition,
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and HIV (Marais and Pai, 2007); (ii) the absence of a practical reference test or gold standard
(Marais et al., 2006); (iii) of the inability of child patients to expectorate sputum (Nelson and
Wells, 2004) (iv) of the nonspecific clinical presentation (Nicol. et al., 2009); (v) of the lower ba‐
cillary load in children which is often smear negative (Detjen et al., 2007) (vi) confirmation by
culture of Mycobacterium tuberculosis, usingthe gold standard of diagnosis in adult TB, rare‐
ly exceeds 30–40% sensitivity (although it may be considerably higher in children with ad‐
vanced disease) (Hesseling et al., 2002) even when using gastric aspirates, induced sputum,
liquid media, and polymerase chain reaction (PCR) (Edwards et al., 2007); vii) distinguishing
between recent primary infection and active disease is highly difficult (Gomez-Pastrana et al.,
2001); viii) gastric aspirates continue to be the best specimens for testing for suspected pulmo‐
nary TB in children (Ling et al., 2011) with 30–40% sensitivity (Hesseling et al., 2002).
Bacteriologic confirmation, the accepted gold standard, is of limited use in children because
of the paucibacillary nature of their disease and poor bacteriologic yields. Sputum smear
microscopy, often the only diagnostic test available in endemic areas, is positive in less than
10 to 15% of children with probable tuberculosis (Schaaf et al., 2006). However, the yield is
high in children with adult-type disease and sputum smear microscopy has definite diagnostic
value in older children (more than 10 year of age) (Cegielski and McMurray, 2004). Culture
yields are also low; reported yields in children with probable tuberculosis are less than 30 to
40% (Schaaf et al., 2006). However, the bacteriologic yield depends on the specific intrathoracic
disease manifestation. A study from South Africa reported a yield of 77% in children with
advanced intrathoracic disease, whereas the yield in those with uncomplicated hilar adenop‐
athy was only 35% (odds ratio, 6.3; 95% confidence interval, 3.2–12.8) (Graham et al., 2001).
This indicates the potential value of sensitive bacteriology-based diagnostic approaches,
particularly in endemic areas where children frequently present with advanced disease.
Most children with TB are classified as smear-negative pulmonary TB (PTB) for the reasons
mentioned above, which is an inappropriate term as a smear or culture has not usually been
done. This leads to difficulties in determining the true extent of PTB in children in different
areas and circumstances. Extrapulmonary TB (EPTB) accounts for up to 20–30% of the total
caseload of TB in children, and the diagnosis is usually easier than PTB because of the
characteristic clinical features like lymphadenopathy with or without scrofula, spinal deform‐
ity, disseminated disease, meningitis, effusions (pleural or pericardial), or painless ascite
(Lewinsohn et al., 2004). The isolation of Mycobacterium tuberculosis takes several weeks.
Consequently, the diagnosis of TB in children is often supported only by epidemiological,
clinical, and radiographic findings in the presence of a positive tuberculin skin test (López
Ávalos and Montes de Oca, 2012).
The value of the classic diagnostic is based on: (1) exposure to an adult index case; (2) chronic
respiratory symptoms that do not respond to broad-spectrum antibiotics; (3) documented
weight loss or failure to thrive; (4) a positive tuberculin skin test (TST); (5) the presence of
suggestive signs on the chest radiograph (CXR), which is greatly reduced in endemic areas
where exposure to and/or infection with M. tuberculosis is common (Marais et al., 2006). These
criteria are less helpful in endemic areas where a positive TST result is common and exposure
to M. tuberculosis is often undocumented (Hesseling et al., 2002). For all these reasons, many
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children with TB are never diagnosed or registered as cases of TB (Nelson and Wells, 2004).
Furthermore, the consequences of missed diagnosis in children are severe, as untreated
children have a high probability of developing active TB, usually within two years of infection
(López Ávalos and Montes de Oca, 2012).
The difficulty to obtain samples for TB diagnosis in children has led researchers to create smart
approaches as “la cuerda dulce” (sweet string), reported by Chow et al., (2006). They provide
a technique which consists of a coiled nylon string inside a gel capsule. The string unravels
through a hole in the end of the weighted capsule as it descends into the stomach and the
capsule then dissolves in it, allowing the string to become coated with gastrointestinal
secretions containing whatever pathogens are present. After about four hours, the capsule is
passed in the feces. This methodology is well tolerated by children and is less invasive than
the gastrointestinal lavage (López Ávalos and Montes de Oca, 2012).
In addition to poor bacteriologic yields, the collection of bacteriologic specimens is often
problematic. Two or three fasting gastric aspirates collected on consecutive days, usually
requiring hospital admission, are routinely performed in young children who cannot cough
up phlegm. A retrospective study from California compared the bacteriologic yield achieved
in gastric aspirates collected from hospitalized and nonhospitalized children. Although the
yield in hospitalized children was higher (percentage of positive cultures, 48 compared to
37%), this difference was not statistically significant, which suggests that hospitalization may
not be a prerequisite for the collection of a good gastric aspirate specimen. Bronchoalveolar
lavage, using flexible fiberoptic bronchoscopy, has additive value when used in combination
with gastric lavage, but this technique is highly specialized and is unavailable in most endemic
areas. In a study from Peru, midmorning nasopharyngeal aspiration was compared with early
morning gastric aspiration; gastric aspiration provided a slightly better yield than nasophar‐
yngeal aspiration (38 compared to 30%), but the results were comparable (Nelson et al., 2004).
Nasopharyngeal aspiration is minimally invasive, does not require hospitalization or fasting,
and can be performed any time of the day. A study from South Africa demonstrated that a
single specimen, using hypertonic saline–induced sputum collection, may provide the same
yield as three gastric aspirate specimens (Corbett et al., 2003). However, the overall yield in
this study remained poor (15% with one and 20% with three induced sputum specimens) and
the technique has not been used outside the hospital setting. Additional studies are awaited
to confirm the feasibility and diagnostic value of collecting induced sputum specimens in
primary health care settings.
Because of the difficulty in achieving bacteriologic confirmation, the diagnosis of childhood
tuberculosis in non- endemic areas is usually based on (1) known contact with an adult index
case (frequently within the household), (2) a positive tuberculin skin test (TST), and (3)
suggestive signs on the chest radiograph. This triad provides a fairly accurate diagnosis in
settings where exposure to M. tuberculosis is rare and well documented. However, its
diagnostic accuracy is greatly reduced in endemic areas where exposure to M. tuberculosis is
common and often undocumented, as exposure frequently occurs outside the household.
Despite reservations about the specificity of the TST response after Bacille Calmette-Guérin
(BCG) vaccination and/or exposure to environmental mycobacteria, a positive TST reaction
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remains a fairly accurate measure of M. tuberculosis infection in immune-competent children.
Current U.S. guidelines recommend the use of three different cutoff points to define a positive
TST reaction. In endemic areas a positive TST is not uncommon in randomly selected healthy
children (Jeena et al., 2002), which limits its diagnostic value. Consequently, the diagnosis of
tuberculosis in children from endemic areas depends mainly on clinical features and the
subjective interpretation of the chest radiograph (Marais et al., 2007). However, chest radiog‐
raphy is unavailable in many endemic areas and it has well-known limitations that may result
in both under- and overdiagnosis of disease (Brent et al., 2007). Despite these limitations it
provides an accurate diagnosis in the majority of symptomatic children with tuberculosis and
the interpretation of the chest radiograph remains the most widely used diagnostic criterion
in clinical practice (Palme et al., 2002).
Various clinical scoring systems have been developed. A critical review of these clinical scoring
systems concluded that they are limited by a lack of standard symptom definitions and
adequate validation (Walls and Shingadia, 2007). Developing standard symptom definitions
through consensus of expert opinion is a difficult and subjective exercise; better guidance may
be provided by objectively measuring the potential diagnostic value of different symptom
definitions. A community-based survey demonstrated that the poorly defined symptoms
traditionally associated with tuberculosis (such as a cough greater than 3 weeks in duration)
are frequently reported in a random selection of healthy children (Bryce et al., 2005). Of 1,397
children without tuberculosis, 253 (26.4%) reported a cough during the preceding 3 months
and 66 (6.9%) reported a cough greater than 3 weeks in duration (Bryce et al., 2005). In addition,
nearly 50% of children with visible hilar adenopathy on the chest radiograph (diagnosed with
tuberculosis) reported no symptoms at all (Bryce et al., 2005). These observations demonstrate
the limited diagnostic value of poorly defined symptoms and the need for improved symptom
and case definitions. In a follow-on study the use of well-defined symptoms with a persistent,
nonremitting character showed greatly improved diagnostic accuracy (Scot et al., 2008).
However, the potential diagnostic value offered by the use of these well-defined symptoms
requires further validation in a prospective, community-based study that includes children
from all relevant risk groups. It is expected that symptom-based diagnostic approaches would
have less value in high-risk children (less than 3 years of age and/or immune compromised)
where disease progression may occur rapidly, emphasizing the need for preventive chemo‐
therapy and early diagnosis of disease in this group (Chintu, et al., 2002). Other diagnostic
modalities may hold promise, but have not shown convincing results to date (WHO, 2006).
Serologic tests are currently unable to diagnose childhood tuberculosis with accuracy, and
sputum-based polymerase chain reaction (PCR) tests have shown variable results and limited
utility (WHO, 2007). Good results were reported with the use of a heminested PCR technique
in Peru, but the study used uninfected children as the control group and therefore could not
evaluate the ability of this novel PCR-based test to differentiate latent infection from active
disease (Upham et al., 2006), which is important, as specific concerns have been raised
regarding the specificity of PCR-based tests.
The diagnostic dilemma is even more pronounced in HIV-infected children. The specificity of
symptom-based diagnostic approaches is reduced by the presence of chronic HIV-related
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symptoms, while the potential window for symptom-based diagnosis is limited by the rapidity
with which disease progression may occur. Chest radiograph interpretation is complicated by
HIV-related comorbidity and atypical disease presentation. These difficulties increase the
potential diagnostic value of sensitive bacteriology-based approaches, to identify HIV-infected
children with tuberculosis (Upham et al., 2002). However, as HIV-infected children are in the
high-risk group the detection of M. tuberculosis infection is also highly relevant. Disease
progression may occur soon (less than 12 months) after primary or reinfection, or latent
infection may be reactivated at a later date because of a decline in immunity. The traditional
TST has poor sensitivity to detect M. tuberculosis infection in HIV-infected children; 50% or
less of HIV-infected children with bacteriologically confirmed tuberculosis are TST positive,
despite using an induration size of at least 5 mm (Upham et al., 2002). This is a major limitation
and development of a more reliable measure of infection will be valuable to identify HIV-
infected children who may benefit from preventive chemotherapy; it may also provide
supportive evidence to establish a diagnosis of active tuberculosis.
3.5.2. Challenges presented by diagnosis of latent infection in children
LTBI, in children as in adults, lacks a diagnostic gold standard. The diagnosis is usually
pursued after a documented household exposure, or to evaluate if chemoprophylactic therapy
is indicated in the context of immunosuppression. In this setting, pre-existing MTB specific
host immune responses are measured to confirm previous infection. Data in adults have
confirmed that IGRA are more sensitive and specific than the TST (Pai et al., 2004; Ferrara et
al., 2006) in this context. Preliminary data suggest IGRA also perform better in children but
age-related data are still sparse. Longitudinal studies assessing their positive predictive value
for the development of active TB are required in both TB-endemic and low-incidence countries,
as the continued exposure in TB endemic settings might yield very different results, compared
to the “one-off” exposure more typically encountered in non-endemic countries.
3.6. Challenges presented by drug resistance
There were an estimated 0.5 million adult cases of MDR-TB in 2007. By the end of 2008, 55
countries and territories had reported at least 1 case of extensively drug-resistant TB (WHO
Report, 2009). Latest research reports published in The Lancet at the end of August 2012,
indicate that researchers have found rates of both multi drug-resistant TB (MDR-TB) and
extensively drug-resistant TB (XDR-TB) higher than previously thought and that they are
threatening global efforts to curb the spread of TB. They contend that most international
recommendations for TB control have been developed for MDR-TB prevalence of up to around
5 percent but that now the world faces a prevalence up to 10 times higher in some places, where
almost half of the patients are transmitting MDR strains. The Researchers who studied rates
of the disease in Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea, and
Thailand are reported to have found that almost 44 percent of cases of MDR TB were also
resistant to at least one second-line drug outline goes here (Dalton et al., 2012)
Comprehensive studies on resistance to anti-TB drugs in children are lacking, because they
are not included in global surveys. Surveillance of anti-TB drug resistance during 1995–2007
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among children from South Africa showed a significant increase in resistance to INH or RIF
from 6.9% to 15.1% and an increase in multidrug resistance from 2.3% to 6.7% (Schaaf et al.,
2009). Drug resistance among children has been documented in clinical trials of both pulmo‐
nary and extrapulmonary TB (Rekha and Swaminathan, 2007). Management of MDR-TB is a
challenge, because it requires prolonged treatment for 24 months with second-line drugs,
which are more toxic and expensive than first-line drugs. According to the 2006 WHO
guidelines for programmatic management of MDR-TB, an optimal regimen should include a
fluoroquinolone, an injectable (capreomycin, kanamycin, or amikacin), and at least 2 of the
following drugs: cycloserine, thiomides, para-amino salicylic acid, and first-line agents other
than INH and RIF (WHO, 2008). Experience with second-line TB drugs in children is limited;
38 children in Peru were treated with supervised, individualized regimens consisting of 5
drugs in the national program. Despite half of these children being anemic and malnourished,
treatment was well tolerated and resulted in a 95% cure rate (Drobac et al., 2006).
There is little published information on optimal treatment of latent TB infection in children in
contact with patients with MDR-TB. In a 30-month follow-up of contacts of patients with MDR-
TB, 5% of children who received appropriate chemoprophylaxis and 20% of those who did not
receive prophylaxis developed disease (Schaaf et al., 2007). Regimens used included INH, PZA,
and ethionamide or EMB. Currently, the best approach may be to perform a complete risk
assessment and clinical evaluation and to individualize therapy, while keeping these children
under close observation. Multicentric trials are urgently required to determine the most
effective drug combinations and optimal duration of chemoprophylaxis for contacts of patients
with MDR-TB.
TB is often not considered in the differential diagnosis in children, especially in low endemic
settings. TB can mimic many common childhood diseases, including pneumonia, generalised
bacterial and viral infections, malnutrition and HIV. However, the main impediment to the
accurate diagnosis of active TB is the paucibacillary nature (containing just a few bacilli) of the
disease in children. Younger children also produce smaller amounts of sputum, which is
usually swallowed rather than expectorated. Bacteriological samples may be collected by
conducting early morning gastric washings, a fairly unpleasant procedure that requires
hospital admission and overnight-fast for up to three consecutive nights. Consequently
bacteriological confirmation is the exception rather than the rule with only 10-15 % of sputum
samples revealing acid fast bacilli (AFB) and culture remaining negative in around 70% of
cases with probable TB (Zar et al., 2005). Without a definitive diagnosis treatment is therefore
often initiated on clinical judgment, aided by algorithms based on exposure history, clinical
features, chest x-ray (CXR) and TST (Marais et al., 2006). Several approaches have been taken
to improve the diagnosis (Marais and Pai, 2007).
3.7. Improving bacteriological detection and rapid resistance analysis
Recent advances in bacteriological and molecular methods for the detection of MTB in patient
samples aim to identify drug-resistance in parallel with detection of MTB. These include the
Microscopic Observation Drug Susceptibility assay (MODS) (Moore et al., 2006), more
sensitive PCR techniques (Sarmiento et al., 2003) or phage-based tests such as FASTPlaque
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(Kalantri et al., 2005). This represents laudable progress, particularly in the context of increas‐
ing drug resistance. Calorimetric culture systems such as the TK medium (Kocagoz et al.,
2004) and electronic-nose technology (Fend et al., 2006) are also under investigation. Among
adults MODS appears to be at least as sensitive as gold standard liquid culture methods (Moore
et al., 2006), Data comparing its performance in children is more limited, but MODS has been
evaluated in a paediatric hospital setting and found to be more sensitive than solid media in
one study (Oberhelman et al., 2006). Data validating other new methods in paediatric speci‐
mens are also lacking, yet performance may be affected by the paucibacillary nature of
childhood TB. The lowest limit of detection of TB by the electronic nose for example has been
reported to be 104 CFU/ml of sputum for example which is just within the range of the expected
bacillary burden in paediatric specimens (Fend et al., 2006). Validation of these assays on
paediatric samples is a research priority (López Ávalos G G and Montes de Oca, 2012). The
introduction of GeneXpert which includes use of integrated DNA extraction and amplification
systems and utilizes real-time PCR (rt-PCR) technology to both diagnose TB and detect
rifampicin resistance, has given a ray of hope with paediatric TB diagnosis and rifampicin
resistance (Gordetsov et al., 2008).
4. Diagnosis and treatment: Current state of affairs
4.1. Classical diagnosis
4.1.1. Clinical symptoms approach
The use of well-defined symptoms improves diagnostic accuracy of pulmonry tuberculo‐
sis  (PTB)  (Imaz  et  al.,  2001).  With  clinical  symptoms  approach  only,  the  status  can  be
classified in two; suspected TB or probable TB. Two situations lead the clinician to sus‐
pect that a child has tuberculosis. The first is a history of chronic illness with clear symp‐
toms: cough and/or fever, weight loss or failure to thrive, an inability to return to normal
health after measles or whooping cough, fatigue, and wheezing; second, is when one or
more of the following: malnutrition, lymphadenopathy, chest signs, hepatomegaly and/or
splenomegaly, meningeal signs, and/or ascites is/are observed. For probable TB, in addi‐
tion  to  suspected  TB,  the  child  presents  with  a  positive  TST,  a  suggestive  radiological
chest  appearing  as  pleural  effusion,  caseation  of  biopsy  material,  poor  response  to  2
weeks  of  antibiotic  treatment,  and/or  favourable  response  to  antituberculous  treatment
(weight gain and loss of signs) (Hesseling et al., 2002).
In pediatric TB, the most common symptoms are pulmonary parenchymal disease and
intrathoracic adenopathy accounting for 60–80% of all cases. Among extrapulmonary mani‐
festations, lymphadenopathy is the most common (67%), followed by central nervous system
involvement (13%), pleural (6%), miliary and/or disseminated TB (5%), and skeletal TB form
(4%). Disseminated disease and TB meningitis are usually found in very young children who
are below the age of 3 years, and/or HIV-infected children (Nelson et al., 2004). TB meningitis
occurs when the child has contact with a suspected or confirmed case.
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In general, there is a sense of skepticism regarding the potential diagnostic value of symptom-
based approaches but nevertheless, the natural history of childhood tuberculosis demonstrates
that symptoms may have diagnostic value if appropriate risk stratification is applied. Marais
et al., (2005), evaluated whether well-defined symptoms have a diagnosis value in children
and a standard symptom-based questionnaire was completed and reported symptoms were
individually characterized. A tuberculin skin test (TST) and chest radiograph (CXR) were
performed in all children. In this study,well-defined symptoms had excellent diagnostic value.
4.1.2. Radiologic studies
Radiography became available after the First World War, and since that time, PTB detection
became easier (Marais et al., 2004). Evidence of pulmonary TB in chest radiographs varies, but
usually radiographs show enlargement of hilar, mediastinal, or subcarinal lymph nodes and
lung parenchymal changes with hilar lymphodenopathy with or without a focal parenchymal
lesion. The most common findings are segmental hyperinflation then atelectasis, alveolar
consolidation, interstitial densities, pleural effusion, and, rarely, a focal mass. Cavitation is rare
in young children but is more common in adolescents, who may develop reactivation disease
similar to that seen in adults (Marais. and Pai, 2007). High-resolution computed tomography
is the most sensitive tool currently available to detect hilar adenopathy and/or early cavitation
(Hesseling et al., 2002).
4.1.3. Diagnostic algorithms
These are point-scoring systems to make diagnostic classifications. Diagnostic algorithms were
developed to deal with these diagnostic difficulties and provide the health care worker with
a rational, stepwise tool to identify children in need of treatment. They are very helpful and
very easy to use in countries with restricted technology, but only few of them are available
especially in resource limited countries (Edwards et al., (2007). Although the natural history
of tuberculosis (TB) in children follows a continuum, the American Thoracic Society (ATS)
definition of stages is useful (Blumberg, et al., 2003). According to the ATS the stages are as
follows:
Stage 1: Exposure has occurred, implying that the child has had recent contact with an adult
who has contagious TB. The child has no physical signs or symptoms and has a negative
tuberculin skin test (TST) result. Chest radiography does not reveal any changes at this stage.
However, not all patients who are exposed become infected, and the TST result may not be
positive for 3 months. Unfortunately, children younger than 5 years may develop disseminated
TB in the form of miliary disease or TB meningitis before the TST result becomes positive. Thus,
a very high index of suspicion is required when a young patient has a history of contact.
Stage 2: This second stage is heralded by a positive TST result. No signs and symptoms occur,
although an incidental chest radiograph may reveal the primary complex.
Stage 3: In stage 3, TB disease occurs and is characterized by the appearance of signs and
symptoms depending on the location of the disease. Radiographic abnormalities may al‐
so be seen.
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Stage 4: Stage 4 is defined as TB with no current disease. This implies that the patient has a
history of previous episodes of TB or abnormal, stable radiographic findings with a significant
reaction to the TST and negative bacteriologic studies. No clinical findings suggesting current
disease are present.
Stage 5: TB is suspected, and the diagnosis is pending. Any patient with pneumonia, pleural
effusion, or a cavitary or mass lesion in the lung that does not improve with standard anti‐
bacterial therapy should be evaluated for tuberculosis (TB). Also, patients with fever of
unknown origin, failure to thrive, significant weight loss, or unexplained lymphadenopathy
should be evaluated for TB (Marais et al., 2006).
4.1.4. Mycobacterial detection and isolation
Microbiological confirmation of TB in young children is not routinely attempted in many high
burden settings due to the difficulty in obtaining samples and the poor performance of smear
microscopy (Nicol and Zar, 2011). Diagnosis of TB still relies primarily on examination of Acid-
Fast Bacilli- (AFB-) stained smears from clinical specimens in adults, however, children with
pulmonary TB usually do not cough up voluntarily, either because they do not produce
sputum or because it produces discomfort. When sputum samples cannot be obtained, gastric
aspirate samples are used for detection and isolation of M. Tuberculosis. Most of the current
TB diagnostic methods were developed over a century ago. In 1898, Neunier became the first
person to culture stomach contents for the evidence of tuberculosis in children (Marais and
Pai, 2007; Lalvani and Millington, 2007), so even with this method, fewer than 20% of children
with TB have a positive AFB smear of sputum or gastric aspirate.
For many years, the collection of three consecutive early morning gastric lavages or gastric
aspirate samples has been the accepted method for attempting microbiological confirmation
even as the yield is very low and that in many populations cannot be performed due to the
lack of infrastructure. In addition low pH is known to kill tuberculous bacilli, indicating that
stomach pH may inhibit TB survival for subsequent culture (Marais. and Pai, 2007). More
recently, a number of less invasive alternative methods have been proposed, including induced
sputum (administration of an inhaled bronchodilator followed by nebulized hypertonic 3–5%
saline and then collecting nasopharyngeal aspiration or expectoration of mucus from lower
respiratory tract). In the nasopharyngeal aspiration, a cannula elicits a cough reflex and the
sweet string test mentioned above (Nicol and Zar, 2011). One of the methods that can be used
to collect samples for microbiological analysis is the string test. This is a non-invasive collection
method and is reported to be well tolerated by children as young as 4 years (Chow et al.,
2006). Inducing sputum after hypertonic saline nebulization has also been shown to be feasible
for young children, although the most widely used procedure is still the early-morning gastric
aspiration or lavage. However, all these procedures involve hospitalization, trained personnel,
and attention to infection control.
All of these alternative ways of sampling have been made to increase yield because a positive
culture is regarded as the “gold standard test” to establish a definitive diagnosis of TB in a
symptomatic child (Hesseling et al., 2002). If culture is negative, diagnosis is made on the basis
of a positive TST. With clinical and radiographic findings suggestive of TB, and history of
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contact with an adult source case, the child may be diagnosed with positive TB based on
symptomatology. This measure was taken because the yields in children are less than 50%.
Zar et al., (2000), investigated whether sputum induction could be successfully performed in
infants and young children with and without HIV and determined the utility of salbutamol-
induced sputum compared to gastric lavage (GL) for the diagnosis of pulmonary tuberculosis.
They concluded that sputum induction can be effectively performed and is well tolerated and
safe even in infants and this induction is better than GL for the isolation of M. tuberculosis in
both HIV-infected and uninfected infants and children.
Although culture on Lowenstein-Jensen medium is considered to be the gold standard, liquid
culture systems (commercial and non commercial) offer the possibility of more rapid and more
sensitive diagnosis of active TB and drug susceptibility but are not widely available in
resource-poor settings (Brittle et al., 2009) compared mycobacterial yields and time to detection
in pediatric clinical samples with use of mycobacterial growth-indicator tubes with those with
use of solid Lowenstein-Jensen slants and found that the yield was substantially higher with
use of mycobacterial growth-indicator tubes (11% compared to 1.6%). Furthermore, the mean
time to detection could be reduced from 18.5 days to 12.4 days with use of a nutrient broth
supplement; newer approaches, such as the colorimetric culture systems and phage-based tests
are of interest, but limited data are available for children.
4.1.5. Smear microscopy
Advances have been done in the performance of smear microscopy for the rapid detection of
MTB, for example, the concentration of specimens by centrifugation or the change of the
staining of carbol fuchsin (Ziehl-Neelsen or Kinyoun) for a fluorescent dyes (auramine-
rhodamine), which both increases sensitivity and reduces the time for screening (Bakir et al.,
2008). However, even under optimal circumstances, the sensitivity of smear microscopy for
the diagnosis of childhood TB remains less than 15%, except in older children with adult-like
disease (Nicol and Zar, 2011).
4.1.6. Tuberculin skin test (TST)
This is one of the major classes of tests that are currently used to detect Latent TB. Tuberculin
which is also called purified protein derivative or PPD is a standardised killed extract of
cultured TB, which is injected into the skin to estimate an individual’s immune response to
TB. There are three methods of testing: the Mantoux test, the Heaf test and the Tine test but
not all of them are currently available for use and some countries prefer one over the other.
The Heaf test is no loner available because its continued manufacture was not economically
viable.
The Tuberculin skin test, or Mantoux TST, is based on the detection of a cutaneous delayed-
type hypersensitivity response to purified protein derivative, a poorly defined mixture of
antigens present in M. tuberculosis, Mycobacterium bovis Bacille Calmette-Guerin (BCG) and
several nontuberculous mycobacteria (Nicol et al., 2011). TST is the standard method for
detecting infection by M. tuberculosis. The reaction is measured as millimeters of induration
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after 48 to 72 hours. This test was the only method available for the diagnosis of latent
tuberculosis infection (LTBI) until very recently.
The Heaf test uses what is called a Heaf gun which uses disposable single-use heads, each head
having six needles arranged in a circle. The device has standard heads and pediatric heads -
the standard head being used on all patients aged 2 years and older while the pediatric head
is for infants under the age of 2. For the standard head, its needles protrude 2 mm when the
gun is actuated while for the pediatric heads, the needles protrude only 1 mm. Before appli‐
cation, the skin is cleaned with alcohol, then 100,000 units/ml (equivalent to about 0.1 ml) of
tuberculin is evenly smeared on the skin and the gun applied to the skin and fired. The excess
of the solution is then wiped off and a waterproof ink mark is drawn around the injection site
as an indicator of the site of administration and the test read 2 to 7 days later. The results of
the test are interpreted as follows:
Grade 0: no reaction, or induration of 3 or less puncture points;Grade 1: induration of four or
more puncture points; Grade 2: induration of the six puncture points coalesce to form a circle;
Grade 3: induration of 5 mm; or more and Grade 4: induration of 10 mm or more, or ulceration.
There is not much difference between the Heaf and Mantoux test, but the two tests can be
related as follows: Heaf grade 0 and 1 approximately equivalent Mantoux less than 5 mm; Heaf
grade 2 approximatley equivalent to Mantoux 5–14 mm and Heaf grade 3 & 4 being approxi‐
mately equivalent to Mantoux 15 mm or greater, To avoid cases of false positives and false
negatives, the tuberculin used for Heaf tests is 1000 times more concentrated than that used
for Mantoux tests. In countries where both tests are used, use of the correct concentration
avoids false positive and false negative results.
The recommended Tuberculin Skin Test (TST), which has now been standardised by the WHO
to contain 0.1 ml of tuberculin (100 units/ ml), is the Mantoux test (CDC, 2010). The dosage of
0.1 ml containing 5 tuberculin units [TU] of purified protein derivative (PPD) should be
injected intradermally into the volar aspect of the forearm using a 27-gauge needle. A detergent
called Tween 80 to prevent loss of efficacy on contact and adsorption by glass stabilizes the
PPD. A wheal should be raised and should measure approximately 6-10 mm in diameter.
Skilled personnel should always read the test 48-72 hours after administration. Measure the
amount of induration and not erythema. This should be measured transverse to the long axis
of the forearm. Multiple puncture tests such as Tine test and Heaf test lack sensitivity and
specificity and hence are not recommended in this situation (Marais et al., 2006).
Subcutaneous injection should be avoided because it results in false negative results. The site
of administration is indicated by a water-proof ink mark drawn around the site of injection to
serve as an indicator for the site. The reading, which is done two to seven days involves
measuring area of induration transversely (left to right) across the forearm and recorded to
the nearest millimetre. It should be borne in mind that the induration (dermal thickening
causing the cutaneous surface to feel thicker and firmer) should not be confused with erythema
(redness of the skin) caused by hyperemia of the capillaries in the lower layers of the skin.
If a patient who has previously had a negative tuberculin skin test develops a positive
tuberculin skin test at a later date, tuberculin conversion is said to have occurred. When such
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a reaction occurs, it provides strong evidence for significant exposure to TB. Different countries
have different standards about the time interval between tests. The UK recommendation is
that the two tests have to be done at least six weeks apart; while in the U.S. the recommendation
is that the two tests can be done one week apart.
Another phenomenon associated with tuberculin skin test is what is called boosting, which
occurs when people who have had some traces of infection with M. tuberculosis and/or
previous exposure to BCG vaccination against tuberculosis, are given repeated tuberculin skin
tests. In these cases, the first test revives or primes the immune response so that on repeat
testing, the response is much stronger and the patient now appears to have a positive reaction.
The second tuberculin skin test result is what is taken to be the correct one. Again, the
guidelines on how to approach the phenomenon of boosting are different in different countries
with the U.S. guidelines emphasising that, ignoring previous immunisation with BCG would
lead to a person showing the phenomenon of boosting, being falsely described as a tuberculin
converter. On the other hand, UK guidelines advocate two tuberculin skin tests one week apart,
if boosting is suspected, taking the result of the second test as being the true result. The
phenomenon of boosting can occur up to two years after the first Mantoux test.
According to the American Academy of Pediatrics (AAP) immediate skin testing is indicated
for the following children: 1)Those who have been in contact with persons with active or
suspected TB; 2) Immigrants from TB-endemic countries or children with travel histories to
these countries; 3) Those who have radiographic or clinical findings suggestive of TB. 4)
Children who are infected with human immunodeficiency virus (HIV) or those living in a
household with persons infected with HIV and; 5) Incarcerated adolescents.
Testing at 2-year to 3-year intervals is indicated if the child has been exposed to high-risk
individuals including those who are homeless, institutionalized adults who are infected with
HIV, users of illicit drugs, residents of nursing homes, and incarcerated adolescents or adults.
Testing when children are aged 4-6 years and 11-16 years is indicated for the following
children:1) Children without risk factors residing in high-prevalence areas; 2) Children whose
parents emigrated from regions of the world with a high prevalence of TB or who have
continued potential exposure by travel to the endemic areas and/or household contact.
Performing an initial TST before the initiation of immunosuppressive therapy is recommended
in any patient (AAP, 1996).
Wit regard to administering the TST to previous recipients of the Bacille Calmette-Guérin
(BCG) several problems are encountered when it comes to interpreting the results of the test.
Immunization with BCG is not a contraindication to the TST but differentiating tuberculin
reactions caused by vaccination with BCG versus reactions caused by infection with M
tuberculosis is difficult. History of contact with a person with contagious TB or emigration
from a country with a high prevalence of TB suggests that the positive results are due to
infection with M tuberculosis. However, multiple BCG vaccinations may increase the likeli‐
hood that the positive TST result is due to the BCG vaccination. The positive reactivity caused
by BCG vaccination generally wanes with the passage of time. With the administration of TST,
this positive tuberculin reactivity may be boosted. However, previous BCG vaccination does
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not affect interpretation of a TST result for a person who is symptomatic or in whom TB is
strongly suspected (Marais et al., 2006).
For the UK the guidelines for interpreting tuberculin skin tests are formulated according to
the Heaf test. For patients who have had BCG previously, latent TB is diagnosed if the Heaf
test is grade 3 or 4 and have no signs or symptoms of active; if the Heaf test is grade 0 or 1,
then the test is repeated and, in patients who have not had BCG previously, latent TB isiag‐
nosed if the Heaf test if grade 2, 3 or 4, and have no signs or symptoms of active TB. Repeat
Heaf testing is not done in patients who have had BCG of the phenomenon of boosting.
The Centers for Disease Control and Prevention (CDC) and the AAP provided recommenda‐
tions regarding the size of the induration created by the TST that is considered a positive result
and indicative of disease [http://www.cdc.gov/tb/]. The TST is interpreted on the basis of 3 "cut
points": 5 mm, 10 mm, and 15 mm. Induration of 5 mm or more is considered a positive TST
result in the following children: 1) Children having close contact with known or suspected
contagious cases of the disease, including those with household contacts with active TB whose
treatment cannot be verified before exposure; 2) Children with immunosuppressive conditions
(such as HIV) or children who are on immunosuppressive medications; 3) Children who have
an abnormal chest radiograph finding consistent with active TB, previously active TB, or
clinical evidence of the disease.
Induration of 10 mm or more is considered a positive TST result in the following children: 1)
Children who are at a higher risk of dissemination of TB disease, including those younger than
5 years or those who are immunosuppressed because of conditions such as lymphoma,
Hodgkin disease, diabetes mellitus, and malnutrition; 2) Children with increased exposure to
the disease, including those who are exposed to adults in high-risk categories (such as
homeless, HIV infected, users of illicit drugs, residents of nursing homes, incarcerated or
institutionalized persons); 3) those who were born in or whose parents were born in high-
prevalence areas of the world; and those with travel histories to high-prevalence areas of the
world. Induration of 15 mm or more is considered a positive TST result in children aged 5
years or older without any risk factors for the disease.
False-positive reactions and false-negative results are common and can be due to various
causes. False-positive reactions are often attributed to asymptomatic infection by environ‐
mental non-TB mycobacteria (due to cross-reactivity). False-negative results, on the other
hand, may be due to vaccination with live-attenuated virus, anergy, immunosuppression,
immune deficiency, or malnutrition. In cases of anergy, a lack of reaction by the body's defence
mechanisms when it comes into contact with foreign substances, the tuberculin reaction will
occur weakly, thus compromising the value of Mantoux testing. For example, anergy is present
in AIDS, a disease which strongly depresses the immune system. Therefore, anergy testing is
advised in cases where suspicion is warranted that it is present. However, routine anergy skin
testing is not recommended. Other factors that may cause a false-negative result include
improper administration (such as subcutaneous injection, injection of too little antigen),
improper storage, and contamination. PPD has been recognized to have an initial false-
negative rate of 29% (Marais et al., 2006).
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With a TST, it is not possible to assert or deny the presence of TB, but it only indicates infection
with a mycobacterium. In a child who has not been BCG-vaccinated, a TST has been defined
as positive when the diameter of skin induration is greater than 10 mm, and in a BCG-
vaccinated child, when the diameter of induration is greater than 15 mm. A negative TST does
not exclude TB and some induration (5–14 mm) could be supportive if the clinical features and
contact history are suggestive (Lewinsohn et al., 2004). Furthermore, the utility of this con‐
ventional test is hampered by technical and logistical problems: potential for false-positive and
false-negative results; problems in administration and interpretation; difficulty in separating
true infection from the effects of prior BCG vaccination, infection due to nontuberculous
mycobacteria (Dogra et al., 2007). In children with debilitating or immunosuppressive
illnesses, malnutrition, or viral (as HIV) and certain bacterial infections, the yield is unknown,
but it is certainly higher than 10%. Moreover, false-positive reactions to TST are often attributed
to asymptomatic infection by environmental nontuberculous mycobacteria (Nicol et al., 2011).
Given that the US guidelines recommend that previous BCG vaccination be ignored in the
interpretation of tuberculin skin tests, false positives are possible. People who have previously
had BCG, will falsely appear to be tuberculin converters and this may lead to treating more
people than necessary, with the possible risk of those patients suffering adverse drug reactions.
However, considering the fact that BCG vaccine is not 100% effective, and that it is less
protective in adults than pediatric patients, not treating these patients could lead to a possible
infection which tennds to justify the current US policy. The U.S. guidelines also allow for
tuberculin skin testing in immunosuppressed patients whereas the UK guidelines recommend
that tuberculin skin tests should not be used for such patients because it is unreliable
4.2. New approaches in TB diagnostics
4.2.1. Polymerase chain reaction (PCR)
Diagnostic PCR is a technique of in vitro DNA amplification that uses specific DNA sequences
(oligonucleotides) as effective fishhooks for the DNA/cDNA of microorganisms. In theory, this
technique can detect a single organism in a lot of specimens such as sputum, gastric aspirate,
pleural fluid, cerebrospinal fluid, blood, and urine. Various PCR assays, mostly using the
mycobacterial insertion element IS6110 as the DNA marker for M. tuberculosis-complex
organisms, have a sensitivity and specificity greater than 90% for detecting pulmonary TB in
adults. This is a rapid, sensitive, specific, and reasonable-cost (Montenegro et al., 2003) method
for the detection of M. tuberculosis in clinical samples. The PCR may be used to (a) diagnose
tuberculosis in difficult samples with negative microscopic examination, negative culture, or
with scarce sample; (b) determine if the organisms in the sample are M. tuberculosis or atypical
mycobacteria; (c) identify the presence of genetic variations like a mutations or deletions
known to be associated with resistance to some antimycobacterial agents (Marais et al., 2005).
Studies in children have obtained better sensitivity by PCR than by culture. In 2001, Gomez-
Pastrana et al., (2001) reported a comparison between sensitivity of culture and PCR showing
higher sensitivity for the latter. PCR may have a special role in the diagnosis of extrapulmonary
TB and pulmonary TB in children since sputum smears are usually unrevealing in these cases.
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However, these tests are not performed correctly in all clinical laboratories. The cost involved,
the need for sophisticated equipment, the limitations in their specificity, the need to obtain
multiple samples to optimize yield and scrupulous technique to avoid cross-contamination of
specimens preclude the use of PCR techniques in many developing countries (Montenegro et
al., 2003).The sensitivity of PCR of gastric lavage/bronchoalveolar lavage has been found to be
56.8% in children with clinically active disease. Authors conclude that nested PCR is a rapid
and sensitive method for the early diagnosis of TB in children. Additionally, other unique
sequences of M. tuberculosis have been suggested as diagnostic test for TB, because they are
absent in M. africanum, M. microti, M. bovis, and M. bovis BCG (Liang et al., 2008).
4.2.2. In-house nucleic acid amplification (NAA) assays
These assays are highly dependent on the operator’s skills. Performance is also influenced by
the choice of target sequence and DNA extraction method. Interpretation of the performance
of these assays in pediatric TB suspects is hindered by the lack of a sensitive and specific
reference standard. When compared with culture, the sensitivity of NAA for the diagnosis of
childhood TB is typically low (40–83%). However, it appears, at least from some reports, that
NAA identified a group of children who are clinically diagnosed with TB but in whom
mycobacterial culture is negative. This means that with a proper technique it could be done
efficiently (Nicol and Zar, 2011 ).
4.2.3. Adenosine deaminase
Adult studies have shown increased levels of adenosine deaminase (ADA) in pleural TB
and TB-caused meningitis,  both  paucibacillary  forms of  TB,  and have  advocated for  its
use  in  diagnosis.  Due  to  this  evidence,  a  serum ADA has  already been  evaluated  in  a
childhood population with a very high sensitivity (100%) and specificity (90.7%) for pul‐
monary TB. This study demonstrated the great potential of this technique because it has
significant difference in serum ADA levels  between children with disease and infection.
However, there were several weaknesses in the study design, including unclear case defi‐
nition, exclusion of nontuberculous patients, and a relatively small TB patient population
(20 with active disease) (Marais. and Pai, 2007).
In the case of extrapulmonary TB, ADA measurement can be helpful, but its sensitivity and
specificity varies widely and has been lower than multiplex PCR using primers for IS6110,
dnaJ, and hsp65. Specifically, a meta-analysis of 63 studies of ADA in tuberculous pleuritis
reveals that the sensitivity of the test is of 0.92 (95% CI 0.90–0.93) and specificity of 0.90 (95%
CI 0.89–0.91) (Lawn and Nicol, 2011).
4.2.4. Serology and antigen detection
In absence of good diagnostic method for tuberculosis, the interest in serodiagnosis has been
increased (Marais et al., 2005). Serological tests vary in a number of features, including antigen
composition (38 kDa, Ag 60, and lipoarabinomannan, LAM), antigen source (native or
recombinant), chemical composition (protein or lipid), extent of antigen(s) purification, and
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immunoglobulin detected. The majority are based on the enzyme-linked immunosorbent
assay (ELISA) rapid versions and use various immunochromatographic formats, with lateral
flow being the most popular.
A recent review of serological tests concluded that commercial antibody detection tests for
extrapulmonary TB have no role in clinical care or case detection (Steingart et al., 2007). The
search for novel biomarkers in blood or urine that can reliably distinguish active from latent
TB in children with and without other co-infections remains an important global goal. Well-
defined cohorts of paediatric patients in TB-endemic and non-endemic settings will be essential
for initial screening and future validation of such potential markers. In the meantime, the
diagnosis of TB in children in resource-poor countries continues to rely on practical algorithms,
which lack standard symptom definitions and adequate validation (Marais et al., 2006). This
poses an increased challenge in the context of HIV infection
Imaz et al., (2001) reported the importance of the recombinant 16-kDa antigen (re-Ag16) of M.
tuberculosis in the serodiagnosis of tuberculosis (TB) in children measuring the values of IgA,
IgM, and IgG and an increased mean antibody response to reAg16 was observed in contact
children compared with nonmycobacterial disease patient with a 95% of specificity. A
combining result of the IgG and IgA assays led to 43% positivity in children with active TB
(Trilling. et al., 2011).
Mycobacterial antigen detection has been evaluated in adults, but rarely in children. Serology
has found little place in the routine diagnosis of tuberculosis in children, even though it is
rapid and does not require specimen from the site of disease. Sensitivity and specificity depend
on the antigen used, gold standard for the diagnosis of tuberculosis, and the type of tubercular
infection. Though most of these tests have high specificity, their sensitivity is poor because
several factors can alter the results such as age, exposure to other mycobacteria, and BCG
vaccination (Marais et al., 2005).
4.2.5. In vitro interferon-γ (IFN-γ) release assays (IGRAs) and antigen-testing
In addition to the traditional TST, which is known to lack both sensitivity and specificity, blood
based assays have recently become available. These T-cell assays rely on stimulation of host
blood cells with MTB specific antigens and measure production of IFN-γ. Numerous published
studies compare the two available commercial assays, T Spot TB (Oxford Immunotec) and
Quantiferon-Gold IT (Cellestis), with the TST for both detection of active disease and LTBI
(Ferrara et al., 2006). T-cell assays have proven to be more specific than the TST, (Arend et al.,
2007) but they are still unable to distinguish between active disease and LTBI. Interpretation
therefore remains dependent on the clinical context. Some few studies have presented
paediatric data but none have provided an assessment of age-related performance of these
assays, and reservations remain regarding their performance in very young children and in
immunocompromised populations, such as those with HIV (Clark et al., 2007).
There is still a lot of on going research aimed at establishing the proper role of gamma
interferon tests and the guidelines ar still under constant review. The interferon-γ release
assays (IGRAs) currently commercially available include QuantiFERON-TB Gold (QFT-G),
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Quanti FERON-TB Gold In-Tube and T-SPOT.TB. These tests are aimed at he body's response
to specific TB antigens not present in other forms of mycobacteria and BCG (ESAT-6). The tests
are not affected by prior BCG vaccination, and despite their being new, these are now becoming
available globally and CDC recommends that QFT-G may be used in all circumstances in which
the TST is currently used, including contact investigations, evaluation of recent immigrants,
and sequential-testing surveillance programs for infection control such as those for health-care
workers. Health Protection Agency (HPA) recommends the use of IGRA testing in health care
workers, if available, in view of the importance of detecting latently infected staff that may go
on to develop active disease and come into contact with immunocompromised patients and
the logistical simplicity of IGRA testing.
4.2.6. GeneXpert MTB/RIF system
GeneXpert includes the development of integrated DNA extraction and amplification systems.
This requires minimal manipulation of sample and operator training. It utilizes real-time PCR
(rt-PCR) technology to both diagnose TB and detect rifampicin resistance. The test amplifies
a region of the rpoB gene of M. tuberculosis. Mutations of this region give rise to 95% of
rifampicin resistance. Resistant strains contain mutations localized within the 81 bp core region
of the bacterial RNA polymerase rpoB gene, which encodes the active site of the enzyme. In
addition, the rpoB core region is flanked by Mycobacterium tuberculosis-specific DNA
sequences. Thus, it is possible to test for M. tuberculosis and for rifampicin resistance simul‐
taneously. The simplicity for the user makes this an assay that could feasibly be widely
implemented outside centralized laboratories and potentially impacts on TB control (Gordet‐
sov et al., (2008). The Xpert system has some advantages over the cultivation, mainly in
specificity and a shorter time to get results (Imaz. et al., 2001).
Recently, Nicol et al., (2011), reported the application of this method in 452 hospitalized
children from South Africa, with or without HIV, with a median age of 19.4 months, and
suspected of having TB. Two Xpert tests doubled the case detection rate compared with smear
microscopy (76% versus 38%), identifying all smear-positive and 61% of smear-negative cases,
the specificity was 98.8%. The sensitivities for smear-negative TB were 33.3% and 61.1% when
testing one or two samples, respectively. The samplings were induced sputum and they
detected three quarters of culture-confirmed tuberculosis with very high specificity; the yield
of this method was twice that of smear microscopy. This could suggest the possibility of
replacing the microscopy for this type of methodology which has greater sensitivity especially
with a second sample (Rachow et al., 2011).
4.2.7. Gas sensor array electronic nose (electronic nose)
The potential to detect different Mycobacterium species in the headspaces of cultures and
sputum samples is another innovative approach that is currently in development. The array
uses 14 sensors to profile a “smell” by assessing the change in each sensor’s electrical properties
when exposed to a specific odour mixture. In an initial study using sputum samples from
patients with culture-confirmed tuberculosis and those without tuberculosis, the E-Nose
correctly predicted 89% of culture-positive patients with a specificity of 91% (Imaz. et al.,
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2001). In a further development applying advanced data extraction and linear discriminant
function analysis, obtained sensitivities were of 68% and 75%, and specificities of 75% and 67%
for Rob and Walter electronic noses, respectively (Imaz. et al., 2001). Further applications of
this test, including its potential value in the diagnosis of child tuberculosis, are needed.
4.3. Diagnosing congenital TB
Congenital TB is rare but symptoms typically develop during the second or third week of life
and include poor feeding, poor weight gain, cough, lethargy, and irritability. Other symptoms
include fever, ear discharge, and skin lesions. The principles in place are that for one to make
a definitive diagnosis of congenital TB, the infant should have proven TB lesions and that it
should have at least one of the following: 1) skin lesions during the first week of life, including
papular lesions (ulcerated areas of the skin) or petechiae (bleeding into the skin); 2) documen‐
tation of TB infection of the placenta or the maternal genital tract; 3) presence of a primary
complex in the liver and 4) the possibility of postnatal transmission should be ruled out. Signs
of congenital TB include failure to thrive, icterus (jaundice or yellow skin), hepatosplenome‐
galy (enlargement of both the liver and spleen), tachypnea (rapid breathing), and lympha‐
denopathy (involving inflammation of lymphnodes) (Marais et al., 2006). Patients with
asymptomatic infection have a positive tuberculin skin test (TST) result, but they do not have
any clinical or radiographic manifestations. Children with asymptomatic infection may be
identified on a routine healthy-child physical examination, or they may be identified subse‐
quent to TB diagnosis in household or other contacts ( for example, children who recently have
immigrated or adopted children). Primary TB is characterized by the absence of any signs on
clinical evaluation. As discussed above, these patients are identified by a positive TST result.
Tuberculin hypersensitivity may be associated with erythema nodosum and phlyctenular
conjunctivitis (Marais et al., 2006).
Endobronchial TB with lymphadenopathy, which is the disease with enlargement of lymph
nodes, is the most common variety of pulmonary TB. Symptoms are the result of impingement
on various structures by the enlarged lymph nodes. Enlargement of lymph nodes and
persistent cough may result in signs suggestive of bronchial obstruction or hemi-diaphrag‐
matic paralysis, whereas difficulty in swallowing may result from esophageal compression.
Vocal cord paralysis may be suggested by hoarseness or difficulty breathing and may occur
as a result of local nerve compression. Dysphagia (swallowing problems) due to esophageal
compression may also be observed. Pleural effusions due to TB may also occur and usually
occur in older children and are rarely associated with miliary disease. The typical history
reveals an acute onset of fever, chest pain that increases in intensity on deep inspiration, and
shortness of breath. Fever usually persists for 14-21 days. Signs include: tachypnea, respiratory
distress, decreased breath sounds, and, occasionally, features of mediastinal shift (moving of
the tissues and organs that comprise the mediastinum) (Marais et al., 2006).
Progression of the pulmonary parenchymal component of TB leads to enlargement of the
caseous area (caseated = cheese-like necrotised tissue) and may lead to pneumonia, atelectasis
(collapse of lung tissue), and air trapping. This is more likely to occur in young children than
in adolescents. The child usually appears ill with symptoms of fever, cough, malaise, and
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weight loss. This condition presents with classic signs of pneumonia, including tachypnea,
nasal flaring, grunting, dullness to percussion, egophony or egobronchophony (increased
resonance of voice sounds, with a high-pitched bleating quality, heard especially over lung
tissue compressed by pleural effusion); decreased breath sounds, and crackles (Marais et al.,
2006). Reactivation of TB disease usually has a sub-acute presentation with weight loss, fever,
cough, and, rarely, hemoptysis (coughing up of blood or bloody sputum from the lungs or
airway). This condition typically occurs in older children and adolescent and is more common
in patients who acquire TB at age 7 years and older. Physical examination results may be
normal or may reveal post-tussive crackles (Marais et al., 2006).
4.4. Diagnosis of extrapulmonary TB
In this case the clinical picture is used to get an indication of the diagnosis. The diagnosis at
any site should be confirmed by obtaining specimens for bacteriology wherever possible. This
means that fluid aspirated or biopsies taken should be placed in a medium such as saline which
will not kill the bacteria. Too often still biopsy specimens are placed in formalin so that
bacteriological confirmation including sensitivity testing cannot be done. Miliary TB may
manifest sub acutely with low-grade fever, malaise, weight loss, and fatigue. A rapid onset of
fever and associated symptoms may also be observed. History of cough and respiratory
distress may be obtained. Physical examination findings include lymphadenopathy, hepatos‐
plenomegaly, and systemic signs including fever. Respiratory signs may evolve to include
tachypnea, cyanosis, and respiratory distress. Other signs, which are subtle and should be
carefully sought in the physical examination, include papular, necrotic, or purpuric lesions on
the skin or choroidal tubercles in the retina (Marais et al., 2006).
Patients with lymphadenopathy (scrofula or deposits in subcutaneous lymphatic ganglia) may
have a history of enlarged nodes. Fever, weight loss, fatigue, and malaise are usually absent
or minimal. One of the most severe complications of TB is TB meningitis, which develops in
5-10% of children younger than 2 years; thereafter, the frequency drops to less than 1%. A very
high index of suspicion is required to make a timely diagnosis because of the insidious onset
of the disease. A sub-acute presentation usually occurs within 3-6 months after the initial
infection. Nonspecific symptoms such as anorexia, weight loss, and fever may be present. After
1-2 weeks, patients may experience vomiting and seizures or alteration in the sensorium (the
part of the cerebral cortex that receives and coordinates all the impulses sent to individual
nerve centers which includes auditory, gustatory, olfactory, somatosensory and visual
centers). Deterioration of mental status, coma, and death may occur despite prompt diagnosis
and early intervention.
Three stages of TB meningitis have been identified. Stage 1 is defined by the absence of focal
or generalized neurologic signs. Possibly, only nonspecific behavioral abnormalities are found.
Stage 2 is characterized by the presence of nuchal rigidity (inability or discomfort during neck
flexion), altered deep tendon reflexes, lethargy (abnormal lack of energy), and/or cranial nerve
palsies. TB meningitis most often affects the sixth cranial nerve due to the pressure of the thick
basilar inflammatory exudates on the cranial nerves or to hydrocephalus; this results in lateral
rectus palsy. The third, fourth, and seventh cranial nerves may also be affected. Funduscopic
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changes may include papilledema (swelling of the optic disc from increased intracranial
pressure) and the presence of choroid tubercles (chroid plexus = vascular proliferation of the
cerebral ventricles that serves to regulate intraventricular pressure by secretion or absorption
of cerebrospinal fluid).which should be carefully sought. Stage 3, the final stage, comprises
major neurologic defects, including coma, seizures, and abnormal movements such as
choreoathetosis (irregular involuntary movements that may involve the face, neck, trunk,
extremities, or respiratory muscles, giving an appearance of restlessness), paresis (slight or
incomplete paralysis), paralysis of one or more extremities. In the terminal phase, decerebrate
(elimination of cerebral brain function) or decorticate posturing, opisthotonus (a type of spasm
in which the head and heels arch backward in extreme hyperextension and the body forms a
reverse bow), and/or death may occur. Patients with tuberculomas or TB brain abscesses may
present with focal neurologic signs. Spinal cord disease may result in the acute development
of spinal block or a transverse myelitis–like syndrome (an abnormal condition characterized
by inflammation of the spinal cord with associated motor or sensory dysfunction). A slowly
ascending paralysis may develop over several months to years.
4.5. Treatment
4.5.1. General treatment overview
Each of the first-line drugs makes a specific contribution during different periods of drug action
(assuming complete drug susceptibility and the absence of significant immune compromise).
Period 1 lasts 2 to 3 days (van der Weert et al., 2006), during which time fast-growing extrac‐
ellular bacilli, comprising the vast majority of the organism load, are killed, mainly by the
excellent bactericidal activity of isoniazid (INH) (Kampmann et al., 2005). Period 2 lasts 4 to 8
weeks. Slower growing extracellular bacilli are killed (van der Weert et al., 2006) and the rate
of killing is determined more by the physiological state of the bacilli and less by the bactericidal
activity of the drug. During this period, the bactericidal activity of rifampin (RIF) is important
and pyrazinamide (PZA) contributes by killing extracellular bacilli that persist in acidic areas
of inflammation (van der Weert et al., 2006). Period 3 lasts 4 to 6 months. Persistent intracellular
bacilli are eradicated mainly by RIF, although INH will continue to offer protection against
the development of resistance and may assist with organism eradication, especially in
fibrocaseous tissue with poor drug penetration. Host immunity plays an important role
throughout, but is of particular importance to effect organism eradication and prevent disease
relapse, as indicated by the high relapse rate in HIV-infected children.
Practical operational issues are extremely important for effective public health intervention.
Operational issues include access to early and accurate diagnosis, the uninterrupted provision
of quality-assured drugs and appropriate treatment regimens, as well as the establishment of
systems to ensure good treatment adherence. Fixed-dose combinations should be used
whenever possible to reduce the risk of drug resistance and to improve simplicity and
adherence, but quality assurance is essential to ensure optimal bioavailability of all the
constituent drugs (Dekker and Lotter, 2003). With proper implementation, the World Health
Organization's directly observed therapy, short-course (DOTS) strategy addresses most of the
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important operational issues. However, the predominant emphasis of the DOTS strategy on
sputum smear–positive disease excludes the vast majority of children. There is a desperate
need to improve service delivery to children with tuberculosis, particularly in endemic areas
with limited resources (Starke, 2002).
4.5.2. Preventive chemotherapy
Chemoprophylaxis refers to preventive treatment given after exposure (without proof of
infection), whereas treatment of latent infection implies that infection (indicated by a positive
TST) was documented. The term preventive chemotherapy is preferred because it is more
inclusive and incorporates both chemoprophylaxis and treatment of latent infection. The TST
is a fairly accurate measure of infection after exposure in immune-competent children,
although TST conversion, which reflects a sufficiently strong delayed-type hypersensitivity
response, may be delayed for up to 3 months (Marais et al., 2004). Therefore, household
exposure, particularly involving high-risk children, should be treated as infection until the
absence of infection can be convincingly demonstrated. In immune-competent children this
can be done by repeating the TST 3 months after exposure ended (American Thoracic Society,
2000). In immunocompromised children the TST is not a sufficiently reliable test to exclude M.
tuberculosis infection and children with documented exposure should receive preventive
chemotherapy as if they are infected (Marais et al., 2006).
The reality on the ground is that most endemic areas do not have the capacity to follow current
World Health Organization guidelines regarding the use of preventive chemotherapy in
children, which advise active tracing and screening of all children less than 5 years old in
household contact with a sputum smear–positive adult source case. This results mainly from
the huge burden of adult tuberculosis and resource constraints that limit the ability to perform
TST and chest X-ray screening tests. Because the TST and chest X-ray are regarded as prereq‐
uisite screening tests, screening of exposed children and the provision of preventive chemo‐
therapy are not even attempted in most resource-constrained areas. Access to preventive
chemotherapy in these settings may be improved by employing symptom-based screening,
although the benefits and risks of such a simplified approach require further evaluation. A
study from an endemic area indicated that symptom-based screening may identify those
children who require further investigation to exclude active tuberculosis (Marais et al., 2006),
thus allowing asymptomatic household contacts, especially those who are at high risk to
progress to disease, immediate access to preventive therapy despite the inability to perform
TST and chest X-ray–based screening (Marais et al., 2006).
Another consideration is that in some endemic areas the majority of disease transmission,
particularly in children greater than 2 to 3 years of age, occurs outside the household (Verver
et al., 2004). In endemic areas, narrowing the focus of contact tracing to those children who are
at highest risk to progress to disease after exposure or infection (less than 3 years of age
and/or immune compromised) will decrease the burden placed on already overstretched
health care systems, while still ensuring access to preventive chemotherapy for the children
who need it most (Van Zyl et al., 2006). In older (greater than 3 years of age), immune-
competent children the risk of tuberculosis after exposure is low and disease progression is
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usually indicated by the presence of persistent, slowly progressive symptoms. Therefore,
passive case finding together with adequate diagnostic vigilance seems appropriate in this
low-risk group.
In non endemic areas where resources permit and where the risk of future reinfection is
low, it seems warranted to extend preventive chemotherapy to low-risk children as well,
to eliminate the reservoir of latent infection within the community. INH monotherapy for
6 to 9 months is the best-studied chemoprophylactic regimen and it reduces the tubercu‐
losis  risk  in  exposed  children  by  at  least  two-thirds;  probably  by  more  than  90% with
good  adherence.  However,  poor  adherence  is  a  major  concern,  particularly  in  endemic
areas (Van Zyl et al., 2006).
In real life the effectiveness of a preventive chemotherapy regimen is determined first by its
efficacy and second by adherence to the prescribed regimen. Because of documented poor
adherence to 6–9 months of unsupervised INH monotherapy, consideration should be given
to alternative preventive strategies with comparable efficacy but with improved adherence.
Theoretically the addition of RIF has important advantages; RIF has strong sterilizing activity
to eradicate latent bacilli and its addition will shorten the duration of treatment required
(Mitchison, 2005). It will also improve efficacy in settings where INH mono-resistance is
prevalent. The use of a 3-month INH and RIF regimen for preventive chemotherapy is well
established and trials have shown equivalence to 6 to 9 months of INH alone, although the
evidence is not as comprehensive as that for INH monotherapy (Ena and Valls, 2005).
PZA is another important sterilizing drug and in theory the combination of RIF and PZA
represents the treatment of choice for latent infection. This combination has proven efficacy in
animal but adverse reactions in adults have limited the initial enthusiasm (Priest, 2004).
However, these adverse reactions have not been observed in children, in whom the three-drug
combination of INH, RIF, and PZA is generally well tolerated (Marais et al., 2006). Adherence
may be improved by shortening the duration of treatment, but consideration may also be given
to the provision of supervised preventive therapy. Creative approaches will be required to
achieve this, particularly in places where health care services are already overburdened. With
curative treatment, intermittent (two or three times weekly) therapy during the continuation
phase is as effective as daily therapy to achieve organism eradication, once the organism load
has been sufficiently reduced (Al-Dossary et al., 2002). The same principle would apply to the
treatment of latent infection, where the organism load is low. Targeting high-risk children for
short-course, supervised intermittent preventive therapy seems achievable, but defining
optimal preventive therapy regimens remains a fertile and important area for future research
(Marais et al., 2006).
Vaccination with BCG is the most widely used preventive strategy, although its efficacy
remains controversial and studies have shown that it contributes to this variable protection:
variations in strain-specific immunogenicity, timing and technique of vaccine administration,
genetic factors, the presence or absence of environmental mycobacteria, and the effect of
multiple re-infection events as may occur in highly endemic areas. It is generally accepted that
BCG vaccination offers significant protection against disseminated disease in young children
(below 2 years), but that it offers little or no protection against adult-type tuberculosis.
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However, reports have documented significant protection against the development of adult-
type tuberculosis when BCG was administered to TST-negative adolescents in locations with
a low prevalence of environmental mycobacterial exposure (Bjarveit et al., 2003).
In addition, a report from Turkey indicated that contrary to the prevailing theory, BCG may
also protect against M. tuberculosis infection as based on a positive enzyme-linked immuno‐
spot result. An even more controversial area is the risk versus benefit that BCG provides to
HIV-infected children. There is a definite risk for HIV-infected infants to develop severe forms
of BCG disease after neonatal BCG vaccination (Hesseling et al., 2006), but it remains poorly
quantified. As the risk:benefit ratio has not been determined, the World Health Organization
still advises BCG vaccination of asymptomatic HIV-exposed infants in tuberculosis endemic
areas. Establishing the risk: benefit ratio of BCG vaccination in HIV-infected infants and the
development of novel vaccines with improved efficacy and safety, remain major research
challenges (Marais et al., 2006).
4.5.3. Curative treatment
The main variables that influence the success of chemotherapy, apart from primary drug
resistance, are the bacterial load and the anatomic distribution of bacilli. Cavitary disease
indicates a high bacterial load, as demonstrated by the frequency with which these patients
are sputum smear–positive, which implies an increased risk for random drug resistance
against individual drugs. Disseminated disease may signify penetration of bacilli into the
central nervous system (CNS) (Van den Bosch et al., 2004) implying that adequate drug
penetration across the blood–brain barrier is an important requirement for the treatment of
disseminated disease (Marais et al., 2006).
From a public health perspective the challenge is to develop a pragmatic classification of
childhood tuberculosis that incorporates the diverse spectrum of disease, but focuses pri‐
marily  on treatment  relevance.  The main variables  that  influence the  success  of  chemo‐
therapy  identify  three  groups  of  children  with  tuberculosis:  (1)  those  with  sputum
smear–negative  disease,  (2)  those  with  sputum  smear–positive  (often  cavitary)  disease
and (3) those with disseminated disease. The discussion reflects current treatment guide‐
lines for these three groups as well  as the new regimens to consider on the basis of es‐
tablished treatment principles (Marais et al., 2006).
As a guide for individual patient classification and management five simple questions have
been formulated: (1) Is the child exposed to or infected with M. tuberculosis? (2) Does the child
have active tuberculosis? (3) If the child is exposed or infected, but does not have active
tuberculosis, is preventive chemotherapy indicated? (4) If the child has active tuberculosis,
what is the appropriate treatment regimen? (5) Are there any special circumstances such as
HIV infection, retreatment, or exposure to a drug-resistant source case to consider? The
underlying rationale is universally applicable irrespective of diagnostic or resource con‐
straints; although areas with access to advanced technology may achieve improved levels of
diagnostic certainty.
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Sputum smear–negative disease is usually paucibacillary and therefore the risk of acquired
drug resistance is low. Drug penetration into the anatomic sites involved is good and the
success of three drugs (INH, RIF, and PZA) during the 2-month intensive phase, and of two
drugs (INH and RIF) during the 4-month continuation phase, is well established. In the
presence of extensive radiographic disease with or without cavitation, and/or suspicion of INH
resistance, the use of ethambutol (EMB) in addition to the three drugs during the intensive
phase should be contemplated. After completion of the intensive phase, successful organism
eradication may be achieved with intermittent (two or three times weekly) therapy during the
continuation phase (Al-Dossary et al., 2002). The efficacy of shorter treatment durations for
HIV-uninfected immune-competent children with sputum smear–negative disease requires
further evaluation, as a 4-month regimen of INH and RIF may be an acceptable therapy for
some adults with sputum smear– and culture-negative tuberculosis.
Sputum smear–positive disease implies a high organism load and an increased risk for random
drug resistance against individual drugs. Selecting drug-resistant mutants is a particular
concern where INH mono-resistance is prevalent, as this increases the likelihood of selecting
multidrug-resistant (MDR) organisms. The use of four drugs (INH, RIF, PZA, and EMB) during
the 2-month intensive phase should reduce this risk. Once the organism load is sufficiently
reduced, intermittent (two or three times weekly) therapy with INH and RIF during the 4-
month continuation phase is sufficient to ensure organism eradication (Al-Dossary et al.,
2002). However, caution should be exercised when initial treatment response has not been
optimal and in HIV-infected patients. The use of long-acting rifamycins together with INH is
discouraged (Rieder et al., 2001).
Disseminated disease is frequently associated with CNS involvement (Donald et al., 2005). It
is therefore essential to consider the cerebrospinal fluid (CSF) penetration of drugs used in the
treatment of disseminated disease. INH and PZA penetrate the CSF well. RIF and streptomycin
penetrate the CSF poorly, but may achieve therapeutic levels in the presence of meningeal
inflammation. The value of streptomycin is limited by poor CSF penetration and intramuscular
administration. EMB hardly penetrates the CSF, even in the presence of meningeal inflamma‐
tion, and has no demonstrated efficacy in the treatment of TBM. Ethionamide shows good CSF
penetration and has been used successfully as a fourth drug in the treatment of TBM. The fact
that RIF penetrates the CSF poorly in the absence of meningeal inflammation reduces its
sterilization value and may warrant the inclusion of PZA during the continuation phase, to
assist with CNS sterilization.
Several reports have illustrated the efficacy of short-course regimens in the treatment of TB
meningitis, but the risk of CNS relapse is rarely reported. In two of these studies a relapse was
documented despite the completion of 6 months of treatment with INH and RIF with an initial
2 months of PZA. Therefore, it seems prudent to include a fourth drug with good CNS
penetration (such as ethionamide) for the treatment of disseminated disease, at least during
the intensive phase, and to consider PZA for the full 6 months of treatment to reduce the risk
of CNS relapse. CNS relapse is rare in the United States, where PZA is routinely discontinued
after 2 months, but the total treatment duration is 9 to 12 months. Current fixed-dose combi‐
nation tablets provide 4 to 6 mg of INH per kilogram. This dose may be suboptimal, particu‐
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larly in settings where the majority of the bacterial population rapidly acetylates INH (Schaaf
et al., 2005). In addition, the serum level achieved with a similar dose of INH per kilogram is
lower in children than in adults, increasing the risk for suboptimal dosing in children (Schaaf
et al., 2005). The majority of new INH resistance encountered in endemic areas is of an
intermediate or low level, which underscores the importance of optimal INH dosing (Donald
et al., 2004). A standard INH dose of 10 mg/kg seems appropriate in children, as even doses
up to 20 mg/kg are well tolerated (Schaaf et al., 2005); children are less susceptible to the toxic
effects of INH than are adults.
In general, adverse events are less common in children than in adults. The most severe adverse
event is the development of hepatotoxicity, which can be caused by INH, RIF, PZA, or
ethionamide. An elevation of liver enzymes (less than five times normal values) is not an
indication to stop treatment, but the occurrence of liver tenderness, hepatomegaly, or jaundice
should prompt the immediate stopping of all potentially hepatotoxic drugs. Jaundice is often
preceded by a period of days or weeks of malaise and nausea. Hepatic reactions usually occur
in the first weeks of therapy, but may happen at any time during the treatment period. Drug-
related hepatic toxicity is usually caused by a single drug, but rarely a combination of drugs,
which individually cause no problem, may cause hepatic toxicity. Children should be screened
for other causes of hepatitis, as in many cases the anti-tuberculosis drugs are not the cause of
liver function derangement. In South Africa, hepatitis A infection is frequently responsible for
non–drug-related liver function derangement in children receiving anti-tuberculosis treat‐
ment. Potentially hepatotoxic drugs should be reintroduced only after liver functions have
normalized. Non-hepatotoxic drugs should be used in the interim and expert opinion should
be sought.
Ethambutol is usually not advised in children less than 7 years as visual acuity cannot be
evaluated. However, its use may be warranted in children with hepatotoxicity, cavitary
disease, or resistance to first-line drugs; it seems safe at recommended dosages. Ethionamide
frequently causes vomiting, but this can usually be overcome by dividing the daily dose and
by a slow increase up to the full dose during the first week or two of therapy. Recommended
dosages for the various first- and second-line drugs are reflected in the publication by Marais
et al., (2006) as indicated in the Table 1 below:
Despite significant symptomatic improvement radiographic disease resolution may take many
months; persistent radiographic signs are not an indication to change treatment if there is
clinical improvement. Paradoxical exacerbation of symptoms or signs may also occur after
anti-tuberculosis therapy is initiated. This results from immune reconstitution with increased
inflammation, particularly surrounding diseased lymph nodes or tuberculomas, that may
follow nutritional rehabilitation (Marais et al., 2004), and/or antiretroviral therapy. The release
of bacterial toxins after successful anti-tuberculosis treatment may also contribute.
Treatment should be continued unaltered, although the temporary addition of corticosteroids
may be considered. Such adjunctive therapy may be helpful in a number of disease manifes‐
tations where the host inflammatory response contributes to disease pathology such as CNS
involvement, severe lymph node compression of the airways, and pericardial effusion. There
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is insufficient evidence to demonstrate whether steroids are effective in tuberculous pleural
effusion.
4.5.4. Retreatment
Anti-tuberculosis treatment rarely fails in children and, if it does, every effort should be made
to find the most likely cause. In settings where the prevalence of drug resistance is low the
commonest cause is failure to properly take the medications, which can occur even during
DOT, if supervision is not complete. It is important to remember that non-adherence has a
differential diagnosis; there are psychologic, sociologic, religious, economic, and practical
reasons why people are non-adherent and one must deal with all these issues for chemotherapy
to be successful. With treatment interruption the child may be restarted on the original
treatment regimen while ensuring adequate supervision, as the risk of developing drug
resistance is small in children with paucibacillary disease. If an immune-competent child
presents with a new episode of tuberculosis more than 6 months after completing treatment
Maximum Dosage (mg/kg/dose)
Mode of Action Daily Two or Three
Times/wk
First-line drugs
Isoniazid Bactericidal 10–15 (300 mg) 20–30 (900 mg)
Rifampin Bactericidal and sterilizing 10–20 (600 mg) 10–20 (600 mg)
Pyrazinamide Sterilizing 20–40 (2,000 mg) 50 (2,000 mg)
Ethambutol Bacteriostatic 15–25 (1,200 mg) 30–50 (2,500 mg)
Second-line drugs
Ethionamide or prothionamide Bactericidal 15–20 (1,000 mg) NA
Streptomycin Bacteriostatic 20–40 (1,000 mg) NA
Fluoroquinolones Bactericidal NA
Ciprofloxacin 20–40 (1,500 mg)
Aminoglycosides Bacteriostatic NA
Kanamycin 15–30 (1,000 mg)
Amikacin 15–30 (1,000 mg)
Capreomycin 15–30 (1,000 mg)
Cycloserine or terizidone Bacteriostatic 10–20 (1,000 mg) NA
Para-aminosalicylic acid Bacteriostatic 200–300 (10 g) NA
NA = not applicable. Source: Marais et al., (2006).
Table 1. First- And Second-Line Antituberculosis Drugs And Recommended Dosages In Children
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for a previous episode, then it most likely represents re-infection disease and standard first-
line treatment is appropriate. In the case of genuine treatment failure (absence of clinical
response to supervised treatment) drug susceptibility testing is of paramount importance. If
an adult source case is identified with drug-resistant tuberculosis, the child should be treated
according to the drug susceptibility pattern of the source case's strain (Marais et al., 2006).
4.5.5. Treatment of paediatric TB/HIV co-infection
The high risk of HIV-infected children to progress to disease after infection justifies the use of
preventive chemotherapy in children who are latently infected. However, the difficult issue
in endemic areas is how to deal with the ever-present risk of undocumented re-infection within
the community. The prevention or reversal of severe immune compromise by using highly
active antiretroviral therapy (HAART) should preclude the need for repeated or continuous
preventive chemotherapy, although the risk for tuberculosis probably remains higher than in
HIV-uninfected children. The cellular immune response assists with organism eradication and
therefore it is not unexpected that disease relapse has been documented in HIV-infected
children. The value of prolonging the treatment duration from 6 to 9 months, to ensure
organism eradication in HIV-infected children, is under investigation. During a repeat episode
both relapse and reinfection should be considered and every effort should be made to establish
a culture-confirmed diagnosis and to do drug susceptibility testing (Marais et al., 2006).
When initiating treatment (curative treatment or RIF-containing preventive therapy) in HIV-
infected children already receiving HAART or for whom HAART is contemplated, it should
be appreciated that the rifamycins, especially RIF, and some of the nonnucleoside reverse
transcriptase inhibitors and/or protease inhibitors may cause significant drug interactions.
HIV-infected children may also develop particularly pronounced paradoxical reactions after
the institution of HAART, because of immune reconstitution inflammatory syndrome.
Recommendations on optimal drug combinations are frequently revised. The most recent
recommendations can be obtained from the Centers for Disease Control and Prevention
website, at [http://www.cdc.gov/nchstp/tb/].
Latest WHO recommendations advise starting antiretroviral therapy (ART) once anti-TB
therapy (ATT) is established (after a period of 2-8 weeks) for all WHO clinical Stage Four HIV-
infected children and Stage Three children with advanced or severe immunosuppression. For
children in WHO clinical stage with mild or no immunosuppression, ART may be deferred
until 6 months of ATT are completed (WHO, 2006). On-going prospective trials involving
adults and children in TB/HIV endemic countries might provide future guidelines for the ideal
timing of the initiation of anti-retroviral therapy (ART) in patients with HIV receiving TB
therapy. There is already evidence from prospective trials that shows that high mortality is
associated with TB in advanced stages of HIV-disease in children who do not receive ART
promptly. Further research is required to improve our understanding of immune reconstitu‐
tion disease (IRD) in children (Walters et al., 2006). Also, therapeutic drug monitoring (TDM),
where available, should be undertaken when children are receiving concomitant ART and
ATT. TDM data from ethnically similar children in resource-rich countries may in the future
inform dosing recommendations in resource-poor settings where TDM is not available.
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4.5.6. Treatment of extrapulmonary paeditric PTB
Treatment is as for pulmonary disease, with isoniazid, rifampicin, pyrazinamide and etham‐
butol for two months followed by isoniazid and rifampicin for four months, except for CNS
disease when treatment should be continued for a full year. Steroids may be used in pericardial
and meningeal disease. Surgery is usually unnecessary, especially where lymph glands and
abscess are present, as long term discharging sinuses may result. Surgery is sometimes
necessary in spinal TB where there is instability and may be needed to overcome strictures in
genito-urinary or gastro-intestinal disease. Occasionally pericardectomy may be required
when pericardial disease causes tamponade.
4.5.7. Treatment of latent paediatric TB infection
Treatment of LTBI, also known as chemoprophylaxis, is important to prevent future disease
activation. The fact that over 50% of hospitalized children with culture-confirmed TB have a
reported close TB contact and do not receive chemoprophylaxis, is an indication of the
important missed opportunities using existing public health interventions. For the last 20 years
the WHO guidelines recommended all children under 5 years in close contact with an
infectious (usually smear positive) case receive 6 months isoniazid. Once active disease has
been excluded, isoniazid monotherapy for 6-9 months has been proven to reduce the TB risk
in exposed children by over 90% with good adherence. More recent studies suggest that 3
months of combined isoniazid and rifampicin are equally effective (Ena and Valls, 2005). In a
recent study with very short follow-up, continuous isoniazid prophylaxis for HIV-infected
children without documented evidence of latent infection, but living in an environment of high
exposure, has also been shown to reduce overall morbidity and mortality from TB and other
infections (Zar et al., 2007). Further trials in HIV-infected children receiving ART are ongoing.
Recommendations for chemoprophylaxis will continue to differ in TB-endemic and non-
endemic settings, because of the perceived risk of exposure. Whilst most paediatricians in
Europe and North America would advocate chemoprophylaxis for HIV infected, TB-exposed
children only, this needs to be interpreted with caution if the exposure is potentially ongoing
or recurrent, and the ability to distinguish LTBI from active disease is limited. In this context,
many practitioners in TB-endemic settings are reluctant to place children on chemoprophylaxis
because of the potential emergence of resistant strains, if indeed the child has active disease
instead of LTBI.
4.5.8. Treatment of drug resistant paediatric TB
Acquisition of resistance rarely occurs in children due to the paucibacillary nature of their
disease but overall, children may also be subject to less selection pressure from anti TB therapy.
Thus most resistance in children is due to primary transmission of a resistant organism, and
MDR /XDR-TB rates in children reflect community transmission rates. Diagnosis requires a
high index of suspicion as the culture yield in children makes definitive microbiological
confirmation difficult. Resistance should be suspected if an index case has known resistant TB;
the child shows initial improvement on anti-TB therapy and then deteriorates; or there is no
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response to initial treatment. Acquired resistance is well described in HIV co-infected adults
previously treated for TB, possibly due to malabsorption of anti-TB drugs (Wells, et al., 2007).
The presence of acquired resistance in the paediatric population is reported and in particular
children with TB/HIV co-infection should be closely monitored (Soeters et al., 2005).
Although the principles of DOTS Plus have been put forward for the management of MDR
TB, at the moment, there is no consensus for any regimen or optimal treatment that should be
used for persons with known exposure to MDR-TB. The recommendation by CDC is a
combination of pyrazinamide and ethambutol, with either pyrazinamide or a fluoroquinolone
and that immunocompetent contacts should be treated for 6 months while immunocompro‐
mised contacts should be treated for 12 months. Current guidelines recommend using at least
four drugs to which the patient is naïve, including an injectable and a fluoroquinolone, in an
initial phase of at least 6 months; followed by at least three of the most active and best tolerated
drugs in a 12-18 month continuation phase.
Standardised regimens have been developed for settings where drug susceptibility testing is
not available (WHO, 2006). Six classes of second-line drugs (SLDs) are available (WHO, 2003)
but experience in children is limited for the majority and multi-centre paediatric trials are
needed. Under optimum circumstances MDR-TB responds well to appropriate therapy.
However delays in diagnosis and treatment, adherence issues, and a lack of child-friendly
formulations and strategies for DOTS all frequently complicate management and contribute
to a high morbidity and mortality (Drobac et al., 2006).
The WHO currently recommends avoidance of chemoprophylaxis in cases of contact with
known MDR-TB and to observe for 2 years if clinically asymptomatic. Children with latent
MDR-TB infection become the reservoir for future transmission following disease reactivation
in adulthood, emphasizing the need to further research and improved management of MDR-
TB infection in children, both at the clinical and operational level.
According to the European Centre for Disease Prevention and Control (ECDC) 2012 Guide‐
lines, there are two valid options to consider for the management of MDR TB and XDR TB
contacts; preventive treatment or follow-up by careful clinical observation. The purpose of
preventive therapy is to prevent the progression of LTBI to TB disease in an individual who
has been exposed to MDR/XDR TB. The concept of preventive therapy has been shown to be
effective for LTBI after contact with drug-susceptible TB but corresponding evidence for
preventive therapy of MDR TB and XDR TB contacts is very scarce. Although for children there
are indications of a positive effect of preventive therapy, for other groups of contacts, the
necessary body of evidence has yet to be generated, and there are ongoing studies to collect
evidence in support of the use of preventive therapy in contacts of MDR TB cases.
There  is  currently  no  evidence  available  on  the  optimal  follow-up  time  in  contacts  of
MDR  TB  or  XDR  TB  with  regard  to  patient  benefits  and  costs  of  the  intervention.  In
young children under five years of age the majority ( over 90%) of TB disease will devel‐
op within 12 months of infection. Infants and children under five years of age, immuno‐
compromised  individuals  due  to  HIV  infection  or  TNF-antagonist  treatment  are  at
increased risk of progression from LTBI to TB disease. These individuals as well as other
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identified risk groups require special  attention as part  of  the individual  risk assessment
(WHO, 2007; Salgado and Solovic et al., 2010).
The optimal duration of MDR-TB treatment in children is not known. World Health Or‐
ganization guidelines recommend treatment until  18 months after  the first  negative cul‐
ture (24 months in XDR-TB). As children often have paucibacillary disease, documenting
a culture conversion is usually difficult. Thus, the same duration as in adults would ap‐
ply. The duration of the intensive phase of treatment (when an injectable drug is given)
should  be  at  least  6  months.  Surgical  resection  should  be  considered  when  the  patient
has localized lesions and has persistently positive smear or culture results inspite of ag‐
gressive chemotherapy (Shah, 2012).
4.5.9. BCG vaccination and HIV infection
Approaches for prevention of TB include prevention of infection (through immunization)
or  of  progression  from latent  infection  to  disease  (chemoprophylaxis).  Bacille  Calmette-
Guérin (BCG) vaccine, a live attenuated vaccine derived from Mycobacterium bovis that
was developed in the 1920s, is administered to children at birth in many countries. WHO
guidelines recommend administration of BCG soon after birth to all  infants in countries
with  a  high  TB  prevalence.  Current  WHO  guidelines  advise  that  all  children  below  5
years  of  age,  who  are  in  close  contact  with  a  sputum  smear-positive  index  patient,
should be actively traced, screened for TB, and provided preventive chemotherapy after
active TB has been excluded (Marais et al., 2004).
Although this is good policy, implementation is fraught with challenges, including difficulty
in diagnosing latent TB in a highly BCG-vaccinated population, ruling out incipient active
disease, and the lack of procedures for documentation and follow-up of contact screening and
chemoprophylaxis in national programs. Because the majority of transmission in children
below 3 years of age occurs in the household and they are also the group at highest risk of
progression to disease after primary infection, this activity should be given higher priority in
national infection-control programs. Moreover, active tracing and screening of household
contacts at high risk would allow children with disease to receive a diagnosis earlier, thus
reducing complications.
Furthermore, additional protection by revaccination with BCG has not been demonstrated
(Rodrigues et al., 2005). To date, the efficacy of the BCG vaccination has not been determined
in HIV infected individuals in whom the immune responses to BCG may be reduced, (Hesseli
et al., 2007) although this is the subject of ongoing trials. Due to the risk of disseminated BCG
disease which may rarely complicate use of this live vaccine in immunocompromised indi‐
viduals, BCG vaccination is no longer recommended in children known to be HIV-infected
(Hesseling et al., 2007). In practice, this has had little impact in HIV-endemic countries, where
the HIV-status of the baby is rarely established at birth, the usual time of BCG vaccination.
A large trial in southern India that included over 350,000 participants aged above 1 year
concluded that BCG vaccine did not offer protection against the development of adult
pulmonary TB (WHO, 2006). However, BCG vaccine has been shown to be protective against
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disseminated forms of TB in young children, with a protective estimate ranging from 67%–
79% against TB meningitis and 58%–87% against miliary disease. A theoretical model esti‐
mated that a universal BCG vaccine program would have a beneficial impact in settings with
prevalence rates of greater than 30 sputum smear-positive cases/100,000 population (WHO,
2007). However, there is no evidence of any BCG-induced protective effect in HIV-infected
children. On the contrary, studies have documented BCG-induced disseminated disease and
adverse reactions. Therefore, the WHO recommendations have been revised, making HIV
infection a contraindication for BCG vaccination, even in settings where TB is highly endemic.
Strategies required for effective implementation of this policy change include high uptake of
maternal HIV testing coupled with implementation of proven strategies to prevent mother-to-
child HIV transmission, including maternal treatment with HAART and early virological
diagnosis of HIV infection in infants, followed by treatment.
The revised recommendations present a dilemma for national programs. Although the benefits
of BCG vaccine far outweigh the risk among HIV-uninfected children living in high areas with
a high prevalence of TB, the risk is higher among HIV-infected infants with or without
symptoms at the time of vaccination. National recommendations will need to consider a variety
of factors, including the prevalence of TB in the population, the prevalence of HIV infection,
the availability of HIV testing and facilities for prevention of mother-to-child transmission
during pregnancy, the capacity to conduct follow-up of vaccinated children, and the availa‐
bility of early infant diagnosis of HIV infection. Abandoning the use of BCG vaccine before
newer vaccines become available may put millions of young children at risk of TB. There is an
urgent need for operational research in TB endemic countries to determine the best way to
manage this issue programmatically.
5. On-going research targeting paediatric TB
5.1. New vaccine pipelines
The global commitment of the WHO and the Stop TB (WHO, 2005) campaign has spurred on
the efforts of the international research community to develop a more effective anti-TB vaccine
by the year 2015. In view of the proven efficacy of existing BCG vaccine in preventing disse‐
minated TB in children and reducing child mortality (Roth et al., 2006) two conceptually
different strategies have been pursued: firstly, the development of ‘priming vaccines’, which,
it is hoped, will replace BCG by providing better and longer protection; secondly, the design
of ‘booster vaccines’ to boost pre-existing BCG-derived immunity. Novel vaccines currently
under development all use a “booster-strategy” after priming with BCG in infancy (Doherty
et al, 2007). As the current candidates are progressing through phase I and II trials, including
studies in HIV-infected individuals and age-de-escalation, it is most likely that more than one
vaccine will progress into phase III.
The most advanced vaccine candidate is MVA- 85A, currently in phase II under a prime-boost
strategy with BCG. Four products are in phase I (72f, Hybrid 1, Aeras 402, rBCG-UreC-Hly),
each stemming from PPPs. Many of the candidates are results from the EU FP6 projects, i.e.
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TBVAC and Muvapred, where valuable progress has been achieved. Several other candidates
are still in the pre-clinical phase. For example, mutation of virulence genes produced a TB
strain potentially conferring greater protection with fewer side effects than BCG. In addition,
an improved, recombinant BCG vaccine with a higher efficacy and a better safety profile
moving into phase I clinical trials is a possible prospect.
New research is directed at the development of a multistage TB vaccine containing latency
antigens, an attractive concept, which is actively being pursued (Andersen, 2007). Such a
vaccine could be used as a booster vaccine with the goal of preventing new infections in those
uninfected with MTB and to prevent reactivation in those with LTBI. Unfortunately, the lack
of reliable correlates of protective immunity currently remains a major obstacle to predict
vaccine efficacy in all TB vaccine trials for both adults and children.
6. Existing research gaps
6.1. Research needs
Tracing of MDR TB contacts is important to prevent TB disease and further transmission.
Priority studies needed include those to identify the most effective contact-tracing procedures
for close contacts and the most effective follow-up procedures in healthcare workers constantly
exposed to MDR TB. As part of the management of MDR TB contacts, studies on specific groups
are needed, for example on children below the age of five years, children with HIV infection
and other immunocompromised states. In particular, studies are needed: 1) for treated
contacts: (randomised) clinical trials: 2) to determine which drugs and which drug combina‐
tions and dosages are optimal for preventive therapy; 3) to determine the duration of preven‐
tive therapy; 4) to assess the effectiveness of preventive therapy in conjunction with
antiretroviral treatment; 5) to assess the risk of development of new drug resistance in contacts
receiving (inadequate and adequate) preventive therapy; 6) for untreated contacts, and
healthcare workers constantly exposed to MDR TB: 7) to identify the optimal follow-up period
for different groups of individuals; and 8) to identify the optimal frequency of testing for LTBI
during the follow-up period.
In order to increase adherence to treatment of MDR/XDR TB contacts (and reduce the risk of
development of new drug resistance in contacts), studies are needed: 1) to identify new drugs
with less adverse events and to explore possible (positive and negative) interactions between
combined drugs; 2) to identify biomarkers indicating the risk of progression from LTBI to TB
disease and 3) to assess operational management to shorten preventive therapy. Since the
provision of preventive therapy has economic and logistic implications at the national and
community level, cost-effectiveness and cost-benefit studies are also needed. These studies are
particularly valuable because they can help to inform the decision on intervention policies..
A substantial amount of funding has been injected into research on various aspects of TB but
there are still many issues that require additional research especially in the area of childhood
tuberculosis. The most salient ones include:1) accurately quantifying the global burden of
Tuberculosis - Current Issues in Diagnosis and Management414
childhood tuberculosis especially in the endemic areas; 2) improving the understanding of the
disease interactions with the immune system and re-evaluating the role of BCG and the new
vaccine candidates in protecting children and adults against TB; 3) defining the diagnostic
contribution of novel T-cell–based assays in endemic and non-endemic areas especially with
regard to diagnosis of paediatric tuberculosis; 4) identifying new ways of diagnosing child‐
hood tuberculosis in HIV negative and in TB/HIV co-infection in children, particularly in
resource-limited settings; 5) carrying out operational research aimed at improving the access
of children in endemic areas to preventive therapy and treatment, using the existing DOTS/
DOTS Plus frameworks; 6) evaluating the efficacy of new short-course intermittent preventive
chemotherapy regimens especially those aimed at childhood TB; 7) exploring shorter durations
of treatment in immune-competent children with smear-negative disease; 8) defining the
optimal treatment regimen and treatment duration in children with TB/HIV co-infection; 9)
monitoring the impact of MDR and XDR tuberculosis on children and evaluating regimens for
effective MDR/XDR disease prevention and treatment; 10) developing and evaluating new
drugs that may shorten the treatment duration and/or assist with the treatment of MDR/XDR
disease and emphasizing case finding and reporting as some of the strategies to combat the
escalation of XDR-TB [http://ec.europa.eu/research/research-eu].
6.2. Need for more specific diagnostic tests
In the field of diagnosis, there is an urgent need to replace sputum microscopy the current gold
standard test, with more sensitive tests that are applicable at point of care. Despite the fact that
the technique can only pick up 60% of cases, it has been in use for over a hundred years.
Furthermore, sputum culture is not suitable for extrapulmonary TB and for paediatric TB since
children can not produce sputum. On the other hand, the newer immunological based tests
such as IGRAs are not well suited for use in TB/HIV co-infection and in high burden TB areas,
where they cannot be accurately used to distinguish active from latent TB. Since the majority
of the infected people never actually develop the disease, there is need to have a diagnostic
tool which is able to distinguish latent from active disease and help to identify healthy
individuals from diseased ones. Improved diagnostics are critical to TB care and control.
The need for serious investment in the critical areas especially in new TB diagnostic tools, drug
susceptibility testing, and development of new biomarkers to enable health providers detect
TB disease activity and to determine follow up treatment outcomes cannot be over emphasised.
The fact that a number of new diagnostic tools are in the pipeline, including culture-based tests
to identify M. tuberculosis and those used to determine drug resistance based on molecular
assays and immune response is good news. However, there is still need to ensure that the new
tests can be availed world-wide and be used at the point-of-care even in resource-poor settings,
where there may be limited technical expertise and the necessary equipment. [http://ec.euro‐
pa.eu/research/research-eu]
6.3. Newer biomarkers for TB disease activity, cure and relapse
There are three major reasons that can be used to justify the need for new TB biomarkers : 1)
a diagnostic test which is able to differentiate between healthy individuals with a latent TB
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infection and patients with active dsease is needed; 2) a prognostic test which can be able to
predict the risk of latent TB becoming active needs to be established; 3) there is need for a
diagnostic test that can be used to serve as a surrogate endpoint of disease which can be used
for monitoring drug and vaccine trials in TB. It is envisaged that the basis for these novel
diagnostic measures will be biomics, comprising metabolomic, proteomic and transcriptomic
profiles in custom-made biosignature. Identification of non invasive biomarkers, especially
the molecular assay of M. tuberculosi fragments in urine and the measurement of volatile
biomarkers of volatile organic compounds generated by Mycobacteria TB in the breath or the
oxidative stress resulting from infection is one step in the right direction. [http://ec.europa.eu/
research/research-eu]
6.4. Need for post-exposure vaccines and those effective against all M. tuberculosis strains
The Bacille Calmette-Guerin (BCG) vaccine is currently the only vaccine in use against
tuberculosis. The efficacy of this vaccine is limited to prevention of severe forms of tuberculosis
among children and there are lots of problems in cases of TB/ HIV coinfection.The current
vaccine candidates are being developed for pre-exposure administration but, considering the
fact that one third of the world’s population is already infected, there is a serious need for a
post-exposure vaccine to prevent re-activation. Another shortcoming with the vaccines in the
pipeline is that they can delay clinical TB but cannot achieve sterile eradication. There is need
for combination vaccines that can combine the effects of booster vaccines with another
generation of vaccines that can act to effect sterilisation at the post-exposure stage. Focus
should also be put on the development of a vaccine that can afford protection against the wide
range of M. tuberculosis strains, to ensure universal effectiveness.To avoid complications in
clinical and epidemiological research, the evaluation of all the vaccines should also deal with
confounding factors such as prior BCG vaccination or HIV status and there should be well
worked out guidelines for use of these vaccines in children [http//www.ec.europa.eu/research/
research-eu]
6.5. Development of new drugs
When it comes to the current status of clinical, diagnostic and therapeutic strategies, childhood
TB has been grossly neglected and there is, therefore need for better and standardized
treatment strategy. Although there is a reasonable number of candidates in the discovery and
pre-clinical pipeline, there are still gaps between the different stages of TB drug development,
and drugs specically targeting paediatric TB are still needed. Most of the drugs in the pipeline
use the same mechanisms with the majority aimed at boosting efficacy or shortening the
duration, with very few targeingt dormant stages of the bacillus and, therefore, not suitable
for eradication of latent infections. Thus urgency for serious research into the development of
new drugs and treatment regimens aimed at achieving this therapeutic objective cannot be
over emphasised. Dealing with TB/HIV co-infection is another gap that needs serious attention:
there is need to develop drugs that can prevent dormant mycobacteria from re-activating in
HIV-positive individuals [http://ec.europa.eu/research/research-eu.
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7. Future prospects
7.1. Reducing the burden of childhood tuberculosis
TB in children presents a number of difficult challenges which will only be solved by a shift
in research priorities. Advances in paediatric TB research will provide wider insights and
opportunities for TB control. While development of a new vaccine to prevent TB should be the
ultimate goal, development of better diagnostics represent one of the most important steps
towards improving individual case management and also providing a more robust case
definition for much needed drug and vaccine trials for studies on TB epidemiology and
correlates of protective immunity in childhood. Data on the epidemiology of childhood TB
may in turn help to inform public health policy by providing a window on current transmission
and the effectiveness of control strategies and by identifying children with LTBI for chemo‐
prophylaxis to limit the future propagation of the epidemic. Emphasis should be placed on
reducing the vulnerability of the community because successful control of the tuberculosis
epidemic is the most effective way to reduce the burden of childhood tuberculosis However,
this will require a holistic approach with sustainable poverty alleviation as a key element
[http://www. ec.europa.eu/research/research-eu].
7.2. Involvement of funders and industry
Important resources are required for the exploration of pathways leading to TB diagnostics-
oriented basic science in pathogen biology, biomarker discovery, systems biology and point
of care test development. The current priorities for TB vaccine development are: i) new vaccine
candidates that achieve sterile eradication, and that can progress into phase II and phase III
trials; ii) vaccine testing in a naïve stage on M. tuberculosis uninfected individuals; iii) vaccines
which can achieve post-exposure prophylaxis to those who are already infected (currently 2
billion people); iv) strategies on how to get vaccines from the research bench to the bedside
and into the community. Apart from the protective effect of novel vaccine candidates, priority
should be given also to their delivery route, formulation (storage, shelf-life and distribution)
and utility for HIV-infected individuals, particularly children.
7.3. Back to basic research
As we talk about nano technology and pin point delivery of drugs it is a shame that 130 years
after the Robert Koch’s discovery of M. Tuberculosis we still have huge gaps in our under‐
standing of the biology, immunology and pathophysiology of the bacillus. We are, as yet, not
able to explain fully the molecular, biochemical and immunological mechanisms that enable
TB infection to go on for years and cause severe disease and death. With the availability of
state-of-the-art molecular research tools such as functional genomics and metabolomics a
paradigm shift towards empahsising basic research could help provide answers to some of the
unanswered questions about M.tuberculosis in general, and paediatric TB in particular. The
currently available knowledge has proved insufficient when it comes to the rational design of
vaccines or other control tools and this has resulted in a lot of trial-and-error approaches. With
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the HIV virus still elusive, defeating the dual alliance of TB/HIV co-infection has added another
diamension in the already complicated war against the resistant strains of M. tuberculosis.
Promoting basic research by providing the necessary resources and involving stakehoolders
on the political front can provide solutions to some of the outstanding problems if not solving
all of them. Where there is will, there is a way [http//ec.europa.eu/research/research-eu].
7.4. Concluding remarks
Recent developments for TB diagnostics seem promising fields due to the fact they are fast and
minimally invasive, but they have drawbacks of not being validated in diverse populations
and improved according to the patient’s needs. Refinement of existing tools and development
and testing of new tools are urgently required to improve diagnosis and treatment of TB in
children. Higher global priority and funding will be required to improve on childhood
nutrition and promote improvement in the socioeconomic and environmental condition of
communities if we are to have a significant impact on TB transmission to children. [Expand
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